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ABSTRACT 
Background and Objectives 
The first six months after the initiation of  HAART is critical. Although 
clinical and immunological improvement is expected, It is not always apparent and 
the drugs may have side-effects. Anaemia and neutropenia ,Sudden and acute bone 
marrow suppression can occur within the first weeks of therapy or present as a slow 
onset of progressive anaemia over months. Most of the toxicity/side-effects can be  
adequately co-managed with efficient clinical monitoring at all levels of the health 
care system. 
Objectives. 
1.To study the Haematological Changes  in Adult HIV Patients following  first line 
HAART initiation. 
2. To study if  there are any contributory baseline  factors for the Haematological 
changes Post HAART. 
Data Collection and the Source. 
 HIV Patients admitted to Medical Units with Haematological changes after initiation 
of first line HAART during the study period. HIV Patients Reviewed at the ART 
Centre at CMCH with Haematological changes   soon( day 15,1 month,6 month) 
after the initiation of first line  HAART during the study period. 
Data collection Methods: 
 All Adult HIV patients between the time period of Aug 2013 till Aug 2014 Who 
developed Haematological Changes Post First Line  HAART initiation  was included 
in the study. 
Sampling Method.  
Prospective  Cohort Study with  Consecutive Sampling  
Sample Size : 52 Patients. 
Case Definitions.  
Defined as per the National Aids Control Organisation (NACO ) HIV/ART  
guidelines ( First line HAART, Anaemia < 10 gms % ). 
Results. 
The  age in the study group ranged from 18-56 with 85 % in the reproductive age 
group. The percentage of severe anaemia <7 were 46.2 % in the study population. 
The most common type of Anaemia in the study was Microcytic Hypo chromic 
Anaemia found in 41% of population. Besides Anaemia there were 13% incidence of 
Pancytopenia and the incidence of Thrombocytopenia was 42 %. There was no 
significant correlation between the occurrence of  Pancytopenia and the baseline CD4 
counts. The second most common pattern was that of Macrocytic Hypo chromic 
Anaemia in about 23 % of patients. Among the clinical symptoms Fatigue and 
dyspnoea were found in 34 % . There was a significant rise  in haemoglobin and 
Hematocrit after the initial drop due to AZT and it was observed especially in those 
patients who developed anaemia within 90 days of ART. The bone marrow findings 
did not bring about any significant correlation . 
Conclusion; 
 There is a significant  rise in Haemoglobin and the Hematocrit  within a median time 
duration of 6 months after the change from AZT based  regimen. 
The Baseline  CD4 counts, Age and Sex did not significantly contribute  to the 
development of Cytopenias in this study but the AZT based regimen had a significant 
impact contributing to all the cases in the study population. 
Keywords: Human Immuno deficiency Virus, Highly active antiretroviral therapy, 
Cytopenias.  
 
  
INTRODUCTION  
Hematologic aberrations are widely seen in Human immune 
deficiency virus-1 (HIV -1) infected patients and they assume significant 
clinical importance in the treatment of a person living with HIV/AIDS ( 
PLHIV). 
HIV causes various disturbances of immune function and  
hematologic defects characterised by Cytopenias of individual as well as 
multilineages of the hematopoietic system. Varying degrees of 
myelosuppression are seen as a part of  the dose limiting toxicities of 
various drugs used in the treatment of HIV and other opportunistic 
infections. 
Though the drugs remain the primary cause of hematologic 
abnormalities there are a wide range of causes linked directly to the 
infection of the blood lymphocytes, monocyte  and macrophages by the 
HIV-1 infection. These effects have been produced by  the marked effects 
on the cytokine production which in turn acts on the hematopoietic 
system producing a range of effects like ineffective haematopoiesis and 
rapid apoptosis.  
 
  
Besides the direct role played by HIV-1 ,other opportunistic 
infections, malignancies, and drugs also do play a significant role in the 
higher incidence of Cytopenias among HIV-1 infected patients . The 
steps taken to correct these  defects like inhibition of HIV replication by 
the use of anti retroviral drugs (ART) ,treatment of opportunistic 
infections and malignancies, substitution of Myelosuppressive 
medications, treatment of the associated nutritional or other deficiencies 
and augmentation of the hematopoietic progenitor cells with recombinant  
factors, in turn facilitates proliferation , differentiation  and maturation of 
all the affected blood cells . 
The specific Cytopenias seen in  asymptomatic HIV -1 infected 
individuals are anaemia occurring in up to 17 % of individuals 
,neutropenia in up to 8 % of individuals, and thrombocytopenia in 13 % 
of individuals and these vary considerably with advancing HIV infection. 
These Cytopenias contribute considerably to the morbidity and the 
mortality associated with the Acquired immune deficiency syndrome 
(AIDS) as the dose reductions and interruptions of the offending drugs 
often lead to the emergence of drug resistance and the progression of the 
disease . 
 
  
Cytop enias are an independent prognostic marker in HIV 
progression and death apart from the CD4, Viral load. ART is helpful in 
combating Neoplasm, Recurrent OI’s, and thereby improving quality of 
life. Among the ART, there is an increased incidence of anaemia in the 
ZDV based regimen, which suppresses the bone marrow by a variety of 
mechanisms.  
This being the one of the leading cause of substitution in the first 6 
months of starting therapy ,and  a detailed study of this event will be 
helpful in the better management of anaemia and other Cytopenias  with 
the ZDV  based ART regimens. 
In the study called the Multicenter AIDS cohort study where the 
incidence of anaemia was calculated among HAART naive and on 
HAART HIV-1 infected patients  it was  observed that about 3.2 % of 
patients were anaemic and they had higher CD4 counts (> 700) and in 
those persons who had low CD4 counts(<250) the incidence was found  
to be about 20.9 %. 
It has also been observed that anaemia and Granulocytopenia 
occurs in a severity which parallels the course of the disease it is not the 
same with thrombocytopenia as it can occur independently at all stages of 
HIV-1 infection. 
  
Unexplained anaemia (<8 g/dl), neutropenia (<0.5 x 109/litre) and 
or chronic thrombocytopenia (<50000), have been described under the 
stage 3 of the WHO staging for adults and adolescents and various studies 
have shown the  improvement of these parameters with increase in CD4 
counts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
AIM OF THE STUDY  
 The aim of the study is to Analyse the Haematological 
changes after the Initiation of First line HAART in adult HIV 
one patient.  
Objective Of The Study  
1.To study the Haematological Changes  in Adult HIV Patients following  
first line HAART initiation. 
2. To study if  there are any contributory baseline  factors for the 
Haematological changes Post HAART. 
 
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
The syndrome of AIDS is caused by Human immune deficiency 
virus which was first reported from the United states in the year 1981 
when it was a chance observation seen in a few patients who had 
Pneumocystis jiroveci (previously called P.Carnii) infection and also had 
Kaposi's sarcoma. These patients were otherwise healthy and were 
homosexual men.  
 
 
  
Soon the disease syndrome was documented among people who 
were intravenous drug abusers, patients who received repeated blood 
transfusions and  in haemophiliacs, in female sexual partners of men who 
had the AIDS symptomatology and also in children born to mothers with 
the AIDS complex. It was in 1983 that the link was established between 
the HIV virus and AIDS when the virus was isolated from a person with 
persistent generalised lymphadenopathy 1 . Subsequently in 1985 a 
diagnostic antibody based testing called the Enzyme linked 
immunosorbant assay(ELISA) was developed as a screening test with 
almost 99 % sensitivity and  since then has become the important 
diagnosing tool to detect HIV . 
The innate  immune systems in the  body produces the defensive  
white  blood cells  and antibodies to  attack  the various infective 
organisms  like the bacteria ,viruses, fungi and parasites that enters the 
body  .These  defensive cells are  the  T-cell lymphocytes, B lymphocytes 
and the natural killer cells. Once the infective organisms namely the HIV  
enters the body and when it starts attacking the T lymphocytes it cause 
the gradual  depletion of the CD4 cells .These CD4 Cells are the primary 
defences against the viruses and other capsulated organisms that enter the 
body 2 .Once the depletion starts the  immune system stands weakened 
and the body stands to be invaded by various diseases caused by the so 
  
called opportunistic infections and also by various malignancies.  
The most common opportunistic infections are Tuberculosis, 
cryptococcosis, candidiasisis, Pneumocystis jiroveci pneumonia , 
Toxoplasmosis,  Cryptosporidiosis, and  Herpes zoster. The common 
malignancies are Kaposi's  sarcoma, primary CNS lymphoma of the brain 
and carcinoma of the cervix to name a few. These various manifestations 
needs to be controlled effectively and there are various measures like the 
Highly active retroviral therapy (HAART) and the treatment for specific 
opportunistic infections which needs to be started early during the course 
of illness to control the disease progression and prolong the survival of 
the patient 3 . 
The Etiologic Agent . 
The etiologic agent is the Human immune deficiency virus (HIV) 
which is part of the retroviridae family and it belongs to the subfamily of 
lentivirdae. 
There are four virus part of the retroviridae group and they are 
Human T Cell lymphocytotropic virus (HTLV I and II) which are mainly 
transforming retrovirus and HIV -1 & 2 which cause mainly cytopathic 
effects (killing the cells )in due course . HIV -1  is the most common 
cause of disease all throughout the world and HIV 2 is predominantly 
found in the  African subcontinent ( mostly in west African patients) 4. 
  
  There are several groups to the viruses and the types associated 
with HIV 1 are ( M,N,O,P) and the subtypes associated with HIV 2 are  
(A-G). The origin of these virus have been traced to a non human primate 
reservoirs. The HIV -1 has been traced to chimpanzees and gorillas and 
the HIV-2 has been traced to sooty mangabeys5,6,7.. The pandemic around 
the world is caused mainly by  HIV-1 M subgroup virus  though 
subgroup O and HIV-2 has also been documented in many more localised 
epidemics in the developed world.   
The group M is called (major), and is responsible for the infections 
in the American and European continents  and the group O is called the  
(outliers),a somewhat rare forms found  in  Cameroon and Gabon and 
another  group N so called because it is novel or it is also called as  non-
M-non- o which is also seen around Cameroon. There are several 
subtypes or clades to these groups and there are also certain forms called 
the circulating recombinant forms which are expanding now greatly 
across the globe . These CRFs are formed by two subtypes that infect the 
same individuals which then recombine that creates a virus with a 
selective advantage8. 
 
 
  
  The geographic distribution of the HIV -1,2 groups ,subgroups ,and 
the various recombinant forms are demonstrated in the figure 1.The 
Subtype C accounts for almost  approximately half of all infections across 
the globe . 
 
                                                      Fig -1 
 
 
  
Epidemiology. 
HIV infection is global pandemic. According to UNAIDS there 
will be 33.3 million Individuals where living with HIV infection at the 
end of 2009. About more than 95% of the people living with HIV/AIDS 
resides in low and middle income countries, of that 50% will be female 
and 2.5million are children less than 15 years. In 2009 the global AIDS 
deaths was totalled around 1.8million that includes 2, 60,000 children less 
than 15years. HIV epidemics have occurred in waves in different regions 
of the world. More than 2/3rd of all peoples with HIV infections live in 
sub Saharan Africa that has only 10-11% of the world's population, 
within that the southern Africa is worst affected. Heterosexual exposure 
is the most common mode of transmission there. 
 In east, south and south east Asia are mostly affected. Among the 
Asian countries, Thailand has an adult seroprevalance rate of >1%. In 
Bangladesh and Pakistan the prevalence has increased very much. In 
United States as of Jan 2010, the total cases estimated were 1,108,611. 
Around 1.1 million individuals were living with HIV infection of which 
21% are unaware of the infection. Around 48% were men who have sex 
with men 9. 
 
  
An estimated 56,000 individuals are newly infected each year. The 
HIV Estimates according to the UNAIDS REPORT 2012, in India alone 
was 20.89 lakh in 2011.  The  sexually active  age-group (15-49) 
prevalence  showed a declining trend   from an  estimated level of 0.41% 
in  2001  to  0.27%  in  2011. Even Though The Estimates Are Declining 
India continues to be the third largest population of (PLHA)  people 
living  with  HIV/AIDS, only behind South Africa and  Nigeria9. 
The first AIDS case was reported from Chennai in 1986 and has 
been reported since then across all the states and union territories. In 1992 
the Indian government launched the National AIDS Control Programme 
(NACP-I) in an all out national effort to control the spread of the 
epidemic. The programme was a comprehensive one with more emphasis 
on Prevention and care. 
This process led to the  formation of the National AIDS control 
board and subsequently National AIDS CONTROL Programme through 
which the Indian government started the free distribution of free HAART 
medications since 2004 and which has continued with amazing success 
till date . 
 
  
 Indian government started the free programme on 1st April 2004 
in the high prevalent states of Karnataka, Tamilnadu, Andhrapradesh, 
Maharashtra, Manipur and Nagaland. In March 2013, there were around 
18  lakhs People Living with HIV (PLHIV) documented in the registry of 
the 400  ART Centres  across India .  
Currently about   6.5  lakhs  are  on  first  line  ART and along with 
this there are about  840 Link ART Centres (LAC) functioning with the 
primary objective of  dispensing the ART  drugs  and monitoring their  
side effects and also for treatment of minor opportunistic infections .out 
of these about 154 LAC have been upgraded to  as LAC plus centres to 
provide  additional Pre ART services.  
The estimated incidence of new HIV infections annually in India is 
around 1.16 lakhs among adults. The  total  number  of  PLHIV  is 
estimated  grossly  at  21  lakhs  in  2011.  the break up is that the  
children  (<15  yrs)  account for 7% ( about 1.45 lakhs). About 39% (8.16 
lakhs) of women are infected and these  estimated numbers  of PLHIV 
have shown a  steady  declining trend from 23.2 lakhs in 2006 to 21 lakhs 
in 201110. 
About 53 % of cases were seen amongst the four high prevalent 
states of South India excluding Kerala. The high risk groups and their 
vulnerability profiles have been different in different parts of the country 
  
and they have been driving the epidemic throughout the country. Various 
prevention  and treatment strategies and have manage to contain the 
epidemic as evidenced by the reduction in the overall incidence of new 
infections besides declining trend in the AIDS related morbidity and 
mortality 10. 
 
Morphology of HIV  
The virus has an icosahedral structure which contains numerous 
external spikes which is formed by the major envelope proteins called the 
external GP 120 and the second protein called the trans membrane protein 
GP 41. The virus gives out virion from the surface of the infected cells  
and it also incorporates various proteins into its lipid bi-layer namely the 
  
Major Histocompatabiliity Proteins (MHC) Class I AND II antigens11. 
The structure of the virus is  
 
  
                                                         Fig -2 
 
 
  
Replication of HIV  
Replication phase I 
 
This starts with the attachment of the virus to the CD 4 (cluster 
differentiated) receptor and to the Chemokine receptor (CCR4/5) that is 
present on the surface of the cell. There are two major co-receptors for 
HIV-1 which belong to the family of the seven trans membrane domain G 
protein coupled cellular receptors and are called the  CCR5 and CXCR4. 
There is also another receptor on the dendritic cell called the (DC-SIGN), 
that binds with a very high affinity to the HIV gp120 envelope protein, 
and this process facilitates the  dendritic cell to bind to the CD4 cells 
when they engage with the CD4 cells. There  occurs endocytosis which 
causes the entry of the virus into the cell followed by the fusion of the 
envelope of the virus with the plasma membrane of the cell that has been 
targeted .The next process in the replication is the uncoating in the 
cytoplasm of the nucleocapsid which happens when there occurs a protein 
called the virion associated cyclophilin A whose presence  actually 
facilitates the process12 .The next process is the reverse transcription of 
the viral Ribose nucleic acid (RNA) to the double stranded viral Deoxy 
ribose nucleic acid (DNA) After this process the viral DNA enters the 
nucleus of the cell as a pre- integration complex that contains the genes 
vpr and integrase .There are certain cellular factors that can block the 
  
progression of infection at this point of the replication cycle .The 
cytoplasmic Protein called the TRIM 5 which has been found in the 
rhesus macaque monkeys has been found to block the simian 
immunodeficiency virus (SIV) replication soon after the virus fuses with 
the host cell.  Another family of proteins called the APOBEC family of 
cellular proteins have also been to inhibit the  progression of virus soon 
after the  virus has entered the cell. These proteins have been found to 
bind to a nascent reverse transcripts and in that process deaminate  the 
viral cytidine thereby causing hyper mutation of the HIV genomes. But 
the confusion remains which among the two processes namely  binding to 
the nascent  reverse transcripts or  the hyper mutations that  kills the 
virus. It  Has been documented that the HIV can escape from the 
APOBEC proteins with the help of the vif gene which cause a 
proteasomal degradation of the targeted proteins thereby protecting the 
virus from the host proteins . After the process of integration the 
integrated linear DNA (now termed the provirus) serves as the template 
for viral transcription. 
  
 
                                                  Figure - 3  
 
 
 
  
Replication phase II 
The process of transcription of the proviral DNA template yields a 
genomic viral RNA and a further process called the splicing of the 
messenger RNA takes place which creates spliced viral  mRNA species 
which encode for the accessory viral proteins  and there are also 
unspliced viral mRNA that are present which encodes for the viral 
structural poly  proteins13.  
 All the transcripts are subsequently exported to the cytoplasm for a 
process called the translation. The viral mRNA is subsequently translated 
into the  proteins which further  undergo post translational  
modification processes like  phosphorylation, glycosylation, cleavage, 
and myristoylation and then occurs the assembly of all the proteins in the 
endoplasmic reticulum. 
 The viral polypeptides are formed by the gathering  of the  HIV 
proteases, vRNA and other constituents of  viral core at the membrane 
described  as the  lipid rafts of the cells that have already accumulated the  
proteins (gp120 and gp41)14. Budding occurs in the lipid bilayer of the 
host cell membrane. where the immature virion core acquires its external 
envelope and it further  undergoes  proteolytic maturation in the 
extracellular milieu.  
  
The mature virion is formed by the subsequent cleavage of the  
gag- pol precursor by virally encoded protease . The entire viral life cycle 
is controlled by numerous regulatory proteins and each of these are a  
potential target for therapeutic intervention.  Until now the targets have 
been the enzymes the reverse transcriptase, protease, and the integrase 
and also the virus –target cell binding and fusion have also been 
successfully targeted to get maximal benefit in disrupting the  viral 
replication and in keeping the infection at bay15. 
The HIV  Genome . 
There are various genes in the HIV-1 (which is structurally more 
complex when compared to HIV 2) that encode for various proteins and 
enzymes. They are the gag which encodes for the core proteins and which 
also includes the p24 antigen. The pol gene encodes for the protease 
which processes the viral proteins, reverse transcription, and 
integration16,17.  
Then  the  env gene  codes  for the structural  envelope 
glycoprotein. There are 6 other genes in HIV 1 namely vif, vpr, and vpu, 
tat, rev, nef, which codes for regulation of viral gene expression 18,19 . 
Besides these genes are the regulatory elements of gene expression called 
the long terminal repeats (LTRs). 
  
The major difference that exists between  HIV-1 and HIV-2 lies in 
the genome in the fact that HIV-2 does not have  the vpu gene but  has an 
extra  vpx gene which is  not seen in HIV-1. The figure - 4 shows the HIV 
proviral genome 20-24. 
                                            Figure - 4 
 
 
 
 
  
Transmission Dynamics. 
HIV is transmitted by various means namely by Blood (either by 
blood transfusion, or by the reusage of IV needles/syringes), by the 
transfer of Deep body fluids (genital secretions, tissue, breast milk) in 
between two persons that can be either heterosexual or homosexual and 
lastly by the vertical transmission from mother to child that can happen at 
any time during and after pregnancy. It has also been documented that 
there is no risk of transmission through mosquito bites. The Risk of HIV 
infection following a single exposure to an HIV infected source are as 
follows, if it is following a Puncture of a health care worker by a 
contaminated needle the risk is  1:313, whereas if is it due to a usage of 
contaminated injection equipment it is about 1:149 and the greatest risk is 
following a blood transfusion  where the risk is 1:1.1 (>95%), the greatest 
following a single exposure to a HIV infected source .  
The Risk of HIV infection following a single sexual  exposure to 
an HIV infected source are as follows .Following a Receptive anal 
intercourse the risk is  1:125 to 1:31, wheras following a Receptive 
vaginal it is about 1:2000 to 1:667. It is about 1:3333 to 1:1111 following 
an Insertive vaginal or anal intercourse, and there are no published 
estimates for oral sex25. The figure - 5 depicts the prevalence of the 
various transmission risks  
  
                                                    Figure  - 5  
 
HIV is and has been predominantly a sexual transmitted disease 
.The various frequencies of transmission per coital act have been 
discussed above .It has been demonstrated the seminal secretions contain 
HIV virus both within the cell free material and amongst the infected 
cellular material.  
During a coital act  a  direct inoculation of the virus  into the  blood 
might happen if there  exists patients with  both the vagina and anal canal 
tears and the infection of the  target cells namely the  Langerhans cells 
  
might happen in the mucosal layer in cases where there is  absence of 
trauma. 
 It has been found  that the Insertive anal intercourse is also equally 
infective when  compared to the Insertive vaginal intercourse.  It has also 
been found that the virus can be transmitted either way to both the  
partners during  a vaginal intercourse.   
Various studies have shown that the male-to-female HIV 
transmission has more risk than the reverse. These might be due to the 
increase time duration of exposure of the vaginal, cervical mucosa and 
the endometrium to infected seminal fluid. When compared with this 
during a coital act among heterosexuals there is only a brief exposure of 
the genital organs to the infected vaginal fluid.  
Other factors that have been studied in depth are the presence of 
co-existing Sexual Transmitted diseases ,and whether the male partner 
has been circumcised  and the presence and absence of  coexisting genital 
ulcers. 
 The infections like Treponema pallidum, Hemophilus ducreyi, 
herpes simplex, Chlamydia trachomatis, Neisseria gonorrhoea and 
trichomonas vaginalis have been associated with high transmission rates 
of HIV infection. 
  
It has also been proved beyond doubt that the treatments of these sexually 
transmitted diseases have reduced the transmission of HIV26. The figure 6 
summarises the risk of transmission in non occupational exposures . 
Figure  6 
 
The quantity of HIV viral load and the CD4 cell counts have significant 
role in the transmission dynamics. The higher the viral load higher the 
transmission and higher the  CD4 cell counts, lower the transmission 
rates.  
 
 
 
  
Pathogenesis. 
Following exposure to and infection with HIV-1 there is a variable 
period of viral replication in mucosal and lymphoid tissue that drains the 
inoculation site and has been codified as Fiebig Stages I–VI 27.  
The appearance of infectious viremia, as determined by infectious 
blood donation studies (time 0), marks a consistent sequence of 
virological and serological events.  
There is a rapid rise in detectable plasma viral RNA at 3–8 days 
(Stage I), followed by p24 antigen and viral DNA by 7–14 days (Stage II 
for p24 antigen alone) with viral RNA and p24 antigen peaking between 
20–30 days.  
The detection of infected peripheral blood mononuclear cells 
(PBMC) coincides with the detection of PBMC-associated viral DNA.  
Anti-HIV IgM appears between 10–17 days post-viremia (Stage 
III), peaks and is followed by a slow rise in the level of anti-HIV IgG 28,29.  
An indeterminate Western blot develops by 15–23 days (Stage IV), 
develops a confirmatory pattern with p24 core and env antibody but no 
antibody to the p31/32 integrase by 47–130 days (Stage V) and then is 
followed by anti-p31/32 thereafter (Stage VI).  
  
During the first 4 months of infection, the level of anti-HIV may 
not be detected by less sensitive immune-enzyme (EI) assay formats (so-
called ‘detuned’ assay); thus, the detuned EI assays may be used to 
determine point incident infection rates.  
Over the ensuing 4–6 months, seroconversion is associated with 
the suppression of the viral replication to a stable viral RNA level or ‘set-
point’ that is prognostic of the risk for disease progression in the 
untreated patient30,31. 
 
 
 
 
  
PERSISTENT VIRAL REPLICATION: 
                   Following the primary infection the  humoral and cellular 
immune responses  are activated but the virus finds a way to  escape the  
immune  mediated clearance and stays in the body itself and is never 
completely eliminated from the body. Within a median of ten years a 
chronic HIV infection sets in which is a hallmark of the HIV disease after 
which the patient becomes ill. There occurs a persistent viral replication 
continuously in the body and this can be detected by highly sensitive 
assays in the circulation and the lymphoid tissues. This persistent 
replication exponentially increases the viral load alongside the destruction 
of the immune system 32. This is different from the Chronicity seen in 
HCV and HBV infection, where the immune system is not the target for 
these viruses and remains intact without manifestations of the 
immunodeficiency syndrome complex. 
Mechanism of Immune Evasion 
                   There are various mechanisms by which the virus evades the 
immune system .The main one is by establishment of continuous viral 
replication with a varied capacity to mutate and recombine. The CD8 
cytotoxic T cells that are produced and expanded during primary HIV 
infection are deleted and made dysfunctional due to the persistent viral 
replication33. The second  mechanisms by which the virus escapes from 
  
immune system is by the lack of recognition of the surface of the HIV 
cell by NEF proteins as a result of the down regulation of the HLA Class 
I molecules.  
The third mechanism that has been demonstrated is the evasion of 
the HIV from the Neutalisin responses by causing hypervariablity in the 
primary sequence and by glycosylation and masking of the neutralising 
epitopes34 .  
One another important mechanisms by which the virus evades is 
the  collection of infected cells in certain places  called reservoir sites 
which are also called immunologically privileged sites and the Central 
nervous system is one such site . Since HIV primarily infects CD4  cells 
and so this loss of those cells damages the  immunologic control. This 
evasion of HIV from the immune response cannot be eliminated by the 
HIV-1  specific cytotoxic cells, so HIV  succeeds in putting strong 
basement creating a state of chronic  infection35. 
HIV reservoir sites: Obstacles to the Eradication of Virus 
         As mentioned above there is a constant pool of latently infected 
resting CD4 cells which causes a persistent reservoir of cells containing 
the virus. There exists two latencies that are called the pre and post 
integration latencies.  This pool of latently infected cells persists even if 
  
the viral load is less than 50 copies as a result of the effect of the potent 
anti - retroviral treatment, and they can persist to produce replication 
competent virus at a later date. The reservoir sites for the HIV infected 
cells are the lymphoid tissue, the peripheral blood and CNS. These 
reservoir sites serves as the major drawbacks in the complete eradication 
of the virus from the human body36,37.  
Early events in HIV 
            The multiplication, establishment and progression of HIV 
infection happens at the lymphoid tissues. The viral replication mainly 
occurs in lymphoid tissues. The cellular response and immune activation 
that follows the viral replication in the lymphoid organs causes the 
lymphadenopathy. It has been shown that the Gut Associated Lymphoid 
Tissue (GALT) is the site of earliest viral replication 38.  
In the early stages of HIV, the architecture of the germinal centre is 
mostly preserved. The follicular dendritic cells trap the antigens and 
present it to the B cells which is the normal physiologic function. In case 
of HIV the trapped virions causes secretion of pro inflammatory 
cytokines such as IL1 beta, TNF alpha, IL6 which will up regulate the 
viral replication. 
  
 CD4 helper cells which goes into germinal centres are susceptible 
to infection by these trapped virions. So in HIV infection the normal 
physiologic function of immune system is affected. As the disease 
progress the germinal centre which was preserved early will undergo 
disruption and swelling, finally to cell death. In the advanced stage of 
disease there is complete disruption and resolution of the follicular 
dendritic cell and finally goes into a stage of burn out.  
This destruction of lymphoid tissue affects both the inability to 
control replication and inability to make immune response 39.  
 
 
 
  
ROLE OF CYTOKINES  
        Cytokines which are the components of immune system play an 
major role in regulating the   HIV-1 expression. The cytokine involved in 
the induction and enhancement of HIV expression are IL 1, IL 2, IL 3, IL 
6, IL18, IL12, TNF alpha, TNF beta, GM-CSF.  TNF alpha, IL 1 beta and 
IL 6 are the potent inducers of HIV expression. IFN alpha, IFN beta, IL 
32 suppress the HIV replication40.  
While TGF beta, IL4, IL10, IFN gamma will induce or suppress 
HIV expression depending on the system involved. The elevation of TNF 
alpha and IL6 are demonstrated in plasma and CSF while TNF alpha, IL 
1 beta, IFN gamma ,IL 6 are demonstrated in the lymph node41. HIV 
replication is controlled by endogenous cytokines which acts 
synergistically in an autocrine and paracrine manner. Finally the secretion 
of some pro inflammatory cytokines is a result of aberrant immune 
activation seen associated with HIV infection42,43. 
Lymphocyte turnover in HIV infection. 
There is an increased turnover in the lymphocyte counts when 
there is an HIV infection inside the body. The turnover decreases with  
the initiation of the cart. The high cell turnover correlates with increased 
cell death as well.  
  
The thymus also plays an important role which has been 
demonstrated by the increase in the levels of T cell receptor excision 
circles (TRECs) after the initiation of HAART. The levels of TREC 
correlates with the changes in thymic output and changes in T cell 
turnover. An increase in thymic output or a decremental response in T 
Cell turnover causes an increase in the levels of TREC . 
Role of Receptors and Co-Receptors. 
The HIV-1  uses the two major co-receptors CCR5 and CXCR4, 
along with CD4 receptor  to bind ,fuse and to the  enter the  target cells; 
The co receptors share their receptor space with some endogenous 
Chemokines .R5 viruses are Strains of HIV which  utilizes the  CCR5 co-
receptor  and X4 Viruses are those which utilize the CXCR4 co receptor. 
There are also certain strains that utilize both the  CCR5 and CXCR4 and 
these are called the dual tropic viruses and they are also called as  R5X4 
viruses.  
There are some natural ligands like the CC-Rantes ( 
CCL5,CCL4,CCL3) which are the natural ligands for the CCR5 receptor 
and these play a major role ( inhibition of binding ) in blocking the entry 
of R5 viruses into the body the SDF-1 plays a similar role with CXCR4 
thereby blocking the X4 viruses. During the early stages of HIV disease 
the transmitting virus is invariably an R5 virus and In 40% of HIV-
  
infected individuals, transition to a predominantly X4 virus  is linked to a 
rapid progression of disease. At least 60% of affected patients  progress 
in their disease  status while predominance of an R5 virus is being 
maintained44. 
Mucosal Transmission of HIV. 
A recently detected receptor is the integrin alpha4/beta7 which 
plays an important role not in the binding to CD4 cells but to the mucosal 
surfaces in the gut and the genital tract 45. It has been demonstrated that 
the virus which binds to this receptor during a sexual exposure binds 
more efficiently than a virus which diversifies over time by mutation. 
Cellular Targets for HIV. 
The various cell lines that can be infected with the HIV are the 
CD4+ T lymphocytes,CD4 cells of  monocyte lineage, Circulating 
dendritic cells, Epidermal Langerhans cells, and the thymic precursor 
cells, though they were assumed to be negative for CD3, CD4, and CD8 
,they actually express low levels of CD4 and hence  can be infected with 
HIV. 
CD4 Dysfunction and Depletion. 
There are certain direct and indirect ways in the dysfunction 
thereby causing  the depletion of the CD4 cells .The direct mechanisms 
  
are the viral budding due to a loss in the plasma membrane integrity, 
unintegrated viral DNA accumulation and interference with processing of 
the cellular RNA, autofusion events involving the intracellular 
glycoprotein 120 and CD4, and lastly the formation of the Syncytia. The 
various indirect mechanisms also exist and they are Autoimmunity, 
Activation-induced cell death and the damaging of antigen coated  
cells 46,47. 
  
 
 
  
GENETIC FACORS IN HIV PATHOGENESIS 
 Several genetic variations have been now identified in human 
beings that influence the risk of acquiring HIV, rate of disease, 
progression, virological control and immune response. There are 
polymorphisms identified in genes in the MHC locus, chemokines, 
cytokines and other host factors. Recently they have identified 
polymorphisms within the HLA-B and HLA-C which is associated 
approximately 15% variation in viral load during the asymptomatic 
period48.  
In some individuals MHC Class I and class II will predispose them 
to an immunopathogenic response particularly in some tissues like CNS, 
Lungs or against some HIV infected cell types such as macrophages, 
dendritic cells, Langerhans cells. There is increased risk of transmission 
of HIV infection among heterosexual Zambian couples who have an 
alleles sharing at HLA-B locus. Also founded HLA heterozygosity for 
class-I loci are associated with delayed onset AIDS in HIV, where as in 
HLA homozygosity it was a reverse.  
Another gene called TAP gene plays an important role in the 
outcome of HIV -1infections. It is also noted that individuals with 
haplotype 8.1 also been correlated with rapid decline in CD4 T cells.  
  
Recent studies shows the single nucleotide polymorphism (SNP) in 
the killer immunoglobulin like receptor (KIR) was found to be strongly 
associated with rapid progression to AIDS. The best example for a 
genetic factor which influences HIV infection and pathogenesis is related 
to the gene which codes for CCR5 the major HIV co-receptor. 
There are individuals who remains uninfected even though after 
repeated sexual exposure to HIV even though in high risk situation. These 
individuals were found to have high resistance with R5 strains of  HIV-I 
but they were readily infected with X4 strains. On various analysis these 
individuals inherited a homozygous defect in the gene that encodes for 
CCR5. They have a homozygous defect for CCR5 32 allele 20% of 
European individuals are heterozygous for CCR5 32 allele and has partial 
resistance or a delayed disease course. Cohort studies from western, 
central Africa and far east Asia has absent CCR5 32 allele.21 
IMMUNE RESPONSE TO HIV 
 Both humoral and cellular immune are very essential in HIV -1. 
These responses are directed against variable antigenic determinants of 
HIV. 
 
 
  
HUMORAL IMMUNE RESPONSE 
Usually the antibodies to HIV will appear within 3-6 weeks 
.Almost invariably within 12 weeks of primary infection. Usually the 
neutralizing antibodies appear after the initial decrease in plasma viremia. 
The antibodies that are detected first are those against envelope gp41 
followed by gag protein p24 and gag precursor p55. gp 120 and gp 41 are 
the only enveloped proteins that elicit neutralizing antibodies.  
The neutralizing antibodies appears in first 6 months, but viruses 
escapes these antibodies. There are 2 types of neutralizing antibodies one 
is type specific antibodies that appears early in the infection and they 
neutralize the viruses of a given strain.  
The other one is group specific neutralising antibodies that appears 
late in infection, which they neutralize a wide variety of HIV. There are 
the 2 types of group specific neutralising antibodies one directed towards 
the CD4 binding site of gp120 and those binding to proximal region of 
gp41. Antibodies directed against gp120 and gp41 also participate in  
antibody dependent cellular cytotoxicity mediate killing of HIV infected 
cells.  
  
There is a entity called bystander killing in which the anti gp130 
antibodies kills uninfected CD4 T cells complement also play an 
important role in humoral immune response. 
 
 
 
  
CELLULAR IMMUNE RESPONSE: 
 Cellular immunity is mediated by CD4 and CD8 and the CD4  cells 
helps the HIV  specific B cells and CD8 T cells in the  direct killing HIV 
infected cells. CD8 T lymphocytes cause the lytic destruction of target 
cells.  
There are 2 types of cytotoxic T lymphocytes the first type directly 
lyses the target cells without prior in vitro stimulation, the other type 
reflects the precursor frequency of cytotoxic T lymphocytes. It is also 
found that there is direct relation between the levels of CD8 T cells 
Capable of producing IFN-gamma to HIV antigen and RNA levels. Some 
of the forms of cell mediated immunity to HIV described are CD8 T cell 
mediated suppression of HIV replication, antibody dependant cellular 
cytotoxicity and NK cell activity 47. 
FACTORS INFLUENCING HIV DISEASE PROGRESSION 
 HOST FACTORS 
 Old age peoples have a rapid progression of the disease, but it was  
an independent predictor in IV drug abusers. The gender do not have any 
major  influence over the disease progression. Ethnicity also doesn't have 
any influence.  
  
It has been studied that 5% of HIV patients will be clinically stable for 
about 10 or more years after seroconversion and they are called as long 
term survivors or long term non progressors.  
COFACTORS 
 HIV patients with CMV seropositivity were found to have 2-4 fold 
higher risk of disease progression. This states that CMV is a cofactor in 
HIV  patients which leads to disease progression. There is no clear cut 
data that EBV ,HHV6, hepatitis B, acts as a cofactor. 
OTHER POTENTIAL COFACTORS 
To infect a cell HIV needs CD4 receptor. Another receptor needed 
to bind and infect the cells are called Chemokine receptor named CCR5. 
In many individuals this CCR5 carry a mutant gene delta32 deletion. If 
the persons are homozygous to delta32 then they found to have less risk 
for the infection with HIV. There are also certain factors cytokines called 
the Stromal derived factor-1 (SDF-1 ) which has affinity to the CXCR4 
receptor. Individuals having mutation of the gene that produces SDF-1 
are more resistant to infection. Association between smoking and CD4 
lymphocyte loss or more rapid disease progression were founded in some 
studies. In developing countries it was studied that malnutrition may 
accelerate the HIV disease progression 49. 
  
MARKERS FOR HIV DISEASE PROGRESSION 
            Certain measurable traits help in disease staging and predicting 
susceptibility to opportunistic infections. Beta2 micro globulin is a non 
specific marker of immune activation. High titre levels are seen in 
association with disease progression. Also higher levels are found in 
various viral infections and in patients with lymphoma.  
Neopterin which is derived from macrophages and B lymphocytes 
is estimated using liquid chromatography and radio immunoassay 
predicts the disease progression. Other conditions having elevated 
neopterin levels are collagen vascular disorders, malignancies and some 
infection.  
Other traits that have some significant role are the soluble CD8,s il- 
2r ,anti p 24 antibody ,anti gp 120 antibody and p24 antigenemia. High 
levels of s IL -2R are found in patients with AIDS and has a negative 
correlation  with CD4 cell counts . Soluble CD8 is an early marker of 
infection and levels correlate with number of  CD8 lymphocytes. Poor 
prognosis is seen in patients with declined anti p24 antibody49 . 
 Absence of the antibody is related to disease progression. p 24 
antigen is transiently seen in acute stages of HIV infection and in latent 
stages of HIV disease. A low CD4 count with p24 antigenemia is a very 
  
strong predictor of disease progression. Some of the HIV isolates who 
have syncitium inducing capacity are seen in  later course of the disease. 
The increased percentage of CD38 positive CD8 T cells reflects a high 
viral load which indicates the disease severity 46. 
DIAGNOSIS OF HIV INFECTION 
Screening tests for the detection of HIV-1  is by ELISA which has 
a sensitivity of more than 99.5%.  But however the confirmatory test in 
the western blot which detects multiple antibodies to HIV proteins. Other 
tests are DNA PCR, RNA PCR, b DNA assay and P24 antigen capture 
assay.  
The p24 antigen capture assay measures HIV-1 core protein in an 
Enzyme linked immuno assay based format. The detection of HIV RNA 
is  by the PCR amplification of the complementary DNA generated from 
viral RNA which is also called the target amplification. 
  Another sensitive measurement of HIV RNA is by measuring the  
branched DNA (bDNA). Measurements of HIV-1 RNA  by isothermic 
nucleic acid amplification with internal controls called the nucleic acid 
sequence–based amplification (NASBA) is also a very sensitive method. 
 
 
 
  
GUIDELINES BY NACO FOR HIV DETECTION 
10 
STRATEGY I 
 This is a strategy which is used for blood donor screening. A single 
ELISA test is done, and if it is found to be negative the donor serum is 
considered free of HIV, if it is positive it is not informed to donors. 
STRATEGY II 
 It is mainly used for the surveillance and diagnostic purposes. Two 
tests are done and the first  test usually an ELISA is negative then the 
sample is considered negative, in contrast if the first test done shows a 
positive result  then the second test  is done and is reported as positive 
when  both the two tests are positive.  
STRATEGY III 
 It  is used in  diagnosing HIV in asymptomatic individuals. This 
strategy uses  a third reactive test which  is needed before reporting a 
positive result. For those symptomatic persons the sample must  be show 
a positive reaction  with 2 different kits and for an person who  is 
asymptomatic and  the same should be positive  with3 different kits. 
 
 
 
 
  
CLINICAL STAGING OF HIV 
 
  
Anti Retro Viral Therapy. 
Pre ART care is attributed to the  period before ART initiation , since 
they are found to have a better immune and clinical staging   Patients who 
do not require ART should be counselled for a good healthy living habits 
and environment and should be linked with health providers and facility 
centres10 .  
1. Baseline screening of CD4. 
2. Baseline lab assessment that includes basic bloods and Urine 
analysis. 
3. Yearly PAP smear testing for women 
4. HBsAg and HCV screening for IDUs. 
The universal goals of ART are to improve the quality of life 
among PLHIV by  reducing the HIV related morbidity and 
mortality by providing maximal and durable suppression of 
viral load and by restoring the immune function .Screening for 
TB is done in every visit, 
All the patients should be assessed clinically by Clinical the 
Stage of HIV disease and the  patient’s past illness and the 
current HIV related illness and also the need for ART and OIs 
prophylaxis should be determined .Other co-existing medical 
  
conditions should be sought after and that may  influence the 
choice of regimen. 
 
 
  
HAART  (Highly Active Anti- retroviral Therapy) 
HAART  is defined when 2 or more NRTIs   are combined with a 
single NNRTI or a Single PI or when a single NRTI is combined with a 
PI and a NNRTI or when a triple NRTI is combined with an Abacavir 
back bone. The Standard drugs as per the NACO guidelines are  
 
 
The HAART drugs used in the NACO programme and that are available 
in India are  
 
  
Mechanism of Action of ART Drugs  
 
NRTIs are analogues of naturally occurring deoxynucleotides, 
thymidine, adenosine, guanosine, cytosine and cytidine. All NRTIs are 
converted into triphosphate forms by intracellular phosphorylation. The 
main mechanism by which the NRTI inhibits viral replication is by due to 
its lack of 3 hydroxyl group on the deoxyribose moiety that prevents the 
further addition of nucleotides to the grouping DNA chain.  
In contrast the non nucleoside reverse transcriptase inhibits binding 
to HIV reverse transcriptase, and competitively inhibits the enzyme and 
thereby prevents the normal movement of protein domain required for 
DNA synthesis50. 
The ART drugs produce a lot of side effects soon after initiation of 
the ART and are divided into short time (2-4 weeks), medium time (2-6 
months),and long term (6-12) months side effects depending on the time 
of onset of the side effect .The haematological side effects which are part 
of the study are usually a short time to medium time side effect and very 
rarely happens after the first 6 month51. 
 
 
 
  
 HEMATOLOGICAL MANIFESTATIONS IN HIV  
HIV - 1 Infection cause an  inherent suppression of  the 
haematopoiesis and the hematopoietic aberrations that are encountered 
are not only  associated with an increase morbidity but also hamper the 
efforts towards controlling the primary viral infections and the associated 
opportunistic infections . 
These lead to an interruption or reduction of the medication doses 
which in turn might lead to the proliferation of the drug resistant 
organisms and also to the progression of infections. Cytopenias in a HIV 
infected patients can affect all the cell lineages individually or can present 
as a Pancytopenia . 
It could be due to an ineffective haematopoiesis, due to a direct 
effect on the  stem cells by the virus, or due to various alterations in the 
hematopoietic growth factors and cytokines, or more commonly due to 
the marrow toxic effect of the ART drugs or due to the invasion of the 
marrow of by the virus ,opportunistic infections and tumour cells and 
lastly by some auto immune destruction of the hematopoietic elements 52. 
Anaemia in HIV. 
It is the frequent Cytopenias seen  with HIV and the severity of 
anaemia has a positive correlation with the clinical stage of the HIV. The 
  
incidence of mild anaemia (a haemoglobin levels of <11 gm%) is about 
13 %in patients receiving HAART and the incidence of Severe anaemia ( 
<9 gm %) has been reported as 5 %. The incidence of anaemia increased 
with the presence of an opportunistic infections and was almost 37 % 
whereas it was 3 % in those who did not have any documented OIs. 
Impaired erythropoiesis has been identified as the foremost cause 
for the anaemia with normocytic and normochromic anaemia being the 
most  common documented type. There has been macrocytosis 
documented mostly with the use of Zidovudine (AZT) and there has been 
a typical decrease in the serum iron with decreases in TIBC as seen in  
chronic diseases. Serum Ferritin have been  observed to be in the higher 
limits which parallels with the severity of HIV infection53,54 .  
The Vitamin B 12 levels have also been found to be  low in HIV -1 
infected patients ,but they do not manifest other manifestations of B- 12 
deficiency. It has been hypothesised that the Virus interferes with the 
transport of the  vitamin rather than the absorption as supplementation 
has not proved to be of any benefit . But with the available limited 
evidence of the role of cobalamin in hindering the attachment  of the 
HIV-1  to  CD4 cell the supplementation of the vitamin might even prove 
useful in  patients who have sub therapeutic levels of the vitamin55-58 . 
  
The incidence of coomb's positive anaemia is staggeringly  high 
among HIV infected individuals with the percentages reaching 85 % in 
those with AIDS and 44 % in non AIDS defining conditions and only 1 % 
in non HIV individuals. This has been attributed to the presence of Auto 
anti bodies to the U and I blood antigens on the erythrocytes and also to 
other non specific antigens on the surface of the erythrocytes. It is due to 
the non-specific binding of anti- antibodies and the deposition of specific 
complexes onto the surface of the erythrocytes .Haemolysis subsequent to 
these auto antibodies mediated destruction has been found to surprisingly 
rare 59 . 
Paraprotienimias as part of the infection in HIV patients also 
contribute to the anaemia. This is mostly polyclonal rather than 
monoclonal and it has been demonstrated by the rouleax formation in the 
peripheral smear and the co migration of the paraprotiens in 
electrophoresis. It has also been documented that these  Paraprotenimias 
do not cause other Cytopenias in HIV patients 59. 
Anaemia in HIV patients have been documented as independent 
risk factor in the morbidity and mortality of the patients. A 1 % change 
(decrease) in the levels of Haemoglobin was shown to correlate with a 50 
% change in the Hazard ratio. Thus the haemoglobin levels are not only 
markers of severity of the infection but also an important prognostic 
  
indicator. Recovery from anaemia has been associated with improved 
survival outcomes. 
Obirikorang & Yeboah60 and Curkendall et al.61 had observed the 
correlation that a  CD4 count of  <200 cells was significantly  associated 
with a severe  grade of anaemia which affected the survival rate and lead 
to a rapid  down hill disease progression. 
 Belperio & Rhew62. and Odunukwe et al63 observed that the role of 
HAART IN suppressing the  viral replication and  in turn the viral load 
and reported the concomitant rise of Hb along with CD4 count rise. 
Some common causes of anaemia in HIV individuals are the 
opportunistic infections which infiltrate the bone marrow like the 
Mycobacterium avium intracellulare,fungal infections like 
Histoplasmosis and malignancies like lymphomas.  
Parvo viral B19 infections which has become persistent in that 
individual are some causes of intractable causes of anaemia .The 
peculiarity of this infection is to selectively infect the replicating 
Erythroid progenitor cells resulting in the decrease in the red blood cell 
mass and Erythroid hypoplasia. 
  
 
 
  
The above picture shows the Erythroblasts which contains viral 
inclusions (thin arrows) at different stages of development. The giant 
proerythroblast on the left (thick arrow) demonstrates chromatin 
condensation at the periphery of the nucleus and a central viral inclusion  
 An intact immune system is needed to mount an action against this 
virus and immunocompromised patients will find it very difficult to clear 
this infection. This infection can be demonstrated by the presence of giant 
pronormoblasts. 
Iron deficiency has been documented in HIV patients and this may 
be due to chronic blood loss states which happens in Kaposi's sarcoma of 
the gut ,CMV colitis and in lymphomas of the gut . Folate deficiency has 
also been documented. These deficiencies can be corrected using 
appropriate supplementation of the nutrients. 
Anaemia commonly occurs following the use of AZT  and it 
manifests as an early side effect ( as early as 15 days ).The characteristic 
features are that the reticulocyte counts are depressed and this may  be the 
first sign of bone marrow toxicity. Bone marrow examinations have 
revealed the complete absence or decrease of  red cell precursors . 
The  myelosuppression cause by AZT  is a transient one  and is 
reversed by using lower doses or discontinuing the drug.It has also been  
  
found that the erythropoietin levels are commonly elevated ( > 500 IU/L) 
which suggests that  the Erythroid hypoplasia is more due to the effect on 
the Erythroid stem cells rather than an interference in erythropoietin 
production. Recombinant Epoeitin has been to be an useful tool in 
treating patients without marked elevation of Erythropoietin levels. An 
associated macrocytosis  has also been found with AZT use with a mean 
elevation of mean corpuscular volume (MCV) by about 25 to 30 units 
commonly and is not necessarily associated with anaemia (A Macrocytic 
normochromic pattern has been observed).This increase in MCV has been 
found to start happening within 6 weeks of initiation and are most 
prominent after about 16 to 24 weeks 64-66.  
 
 
  
Neutropenia 
Granulocytopenia is  seen to  occur concomitantly with anaemia . 
The prevelance  of neutropenia in HIV infected patients is about 30 % 
and the peripheral smear of those patients reveal a variable decrease in 
the neutrophils ,lymphocytes, and monocytes with the classical 
hypolobulation of the neutrophis which is commonly seen with a left 
shift. Vacuolization of the blood monocyte are also frequently observed . 
The cause of leucopoenia  has been attributed to the impairment of 
the myelopoiesis and the myelotoxic drugs are the frontrunners as the 
causative agents in almost 80% of patients. Some patients have been 
found to have some circulating antibodies on their cell surface  .The HIV 
infection has both direct and indirect effect on the granulocyte numbers 
which causes a steady decline in the oxidative and chemotactive 
capabilities. 
There also occurs a steady increase in the apoptosis rate. A 
qualitative defect in the neutrophils have been observed in the HIV 
Patient and these defects make the neutrophils less pliable with respect to 
diapedesis and these defects tend to correct with the administration of 
Colony stimulating factors (Granulocyte -Monocyte colony stimulating 
factors-GMCSF) and also with the initiation of HAART . 
  
There has been even reports of deficiencies in the production of G-
CSF in response to neutropenia although the response to other febrile 
episodes appears normal. About a third of patients  also have anti - 
neutrophils antibodies but this does not have  any correlation with the 
severity of neutropenia.  
Granulocytopenia in HIV patients significantly increases the risk of 
severe bacterial infections 67-71 . 
 
 
 
 
  
Drugs associated with Neutropenia. 
 The drugs  that are used in the setting of HIV that  are frequently 
associated with neutropenia are Ganciclovir-40%, 2nd week, Zidovudine, 
Trimethoprim-sulfamethoxazole, Pentamidine ,Rifabutin and Dapsone.  
Thrombocytopenia in HIV. 
 Thrombocytopenia in HIV is unique since it can occur at any stage 
of HIV disease ,independentently of other Cytopenias and its severity 
does not parallel with that of the HIV disease .The incidence of 
thrombocytopenia is about 60 % in all stages of HIV irrespective of the 
risk groups and among these about 16-40 % may present with severe 
thrombocytopenia ( < 50,000) and may manifest bleeding manifestations . 
 Thrombocytopenia is neither a prognostic indicator nor plays a 
significant role in the morbidity outcomes. The cause of 
thrombocytopenia is either immune destruction or decrease production .In 
earlier stages of disease it has been found that immune destruction plays a 
predominant role whereas decrease production takes predominance in the 
late stages. 
 Majority of HIV patients have antibody coated immune complexes 
on the surface of the platelets .These are mostly non specific complexes 
which are seen .More specific complexes are seen when there are occurs 
  
a molecular similarity  existing between  GP120/160 of HIV -1 virus and 
the GPIIB/IIIA of the platelets and these complexes coat the surface with 
much vigor. 
 This process causes more destruction of the platelets and the life 
span of those cells decrease by about 2/3 rd's after the antibodies have 
been detected and also it has been found that the presence of antibodies. 
Besides the immune destruction other infections and fevers can also play 
a significant role in decreasing the life span of the circulating platelets. 
 The other mechanisms of decreased platelet count are due to 
Splenomegaly which causes sequestration of platelets, and non immune 
destruction of platelets as occurs in the hemolytic uremic syndrome and 
thrombotic thrombocytopenic purpura which is found to occur more 
frequently  in HIV infected patients 72,73 . 
 Even though the megakaryopoiesis is stimulated there is a steady 
decrease in the production capability of the megakaryocytes which 
counters the peripheral destruction .The precursors demonstrate a 
significant raise in apoptosis when it is compared with non HIV patients 
and Various studies have shown an inverse relationship with circulating 
platelets. 
  
 Other mechanisms are that the HIV-1 might directly target the 
megakaryocytes and thereby suppressing the platelet production and the 
numbers may be low and there may occur qualitative and morphologic 
changes amongst the megakaryocytes.  
 The virus also alter the antigens on the surface of the 
megakaryocytes and makes them as sitting ducks for antiplatelet 
antibodies .There are various  dysregulations that are  found in the growth 
factors and the cytokines in  HIV patients which can alter the platelet 
production reducing it numbers. 
 HIV associated Thrombocytopenia is a difficult situation to treat 
with as there are no published randomized trials on the treatment of 
thrombocytopenia. There have been anecdotal reports of spontaneous 
remission .Sudden increase in the platelet counts are associated with a 
deterioration of the immune system and that might be a forerunner for the 
AIDS complex . In patients with decrease in the counts there is no 
necessary to treat as the bleeding in those patients seldom occur despite a 
low platelet count74-76 . 
 Some time AZT treatment might result in the increase of the 
platelet counts in 30 %of patients and this results can be seen within 8-12 
weeks after initiation of AZT based HAART. Dapsone has also shown a 
similar effect on the Platelet counts and the mechanism by which it 
  
happens has been postulated due to a decrease in the phagocyte mediated 
destruction of the cells. 
 Corticosteroids have also been tried to increase the platelet counts 
with varying results .There are other modalities which have been tried to 
improve the platelet counts and they are anabolic steroids and vincristine . 
 The response rate for vincristine has been around 10 % and high 
dose ascorbic acid has also been to show better results when given in 
small quantities over several months. Interferon alpha has also been tried 
mostly in AZT resistant thrombocytopenia and the response has been 
good in almost 70 % of patients and the mechanism by which Interferon 
acts has been postulated as by increasing the IL - 6 levels which has a 
trophic effect on platelets. 
 Gamma globulin infusion has shown to cause rapid rise in platelet 
counts and the median time duration has been in the order of 3-4 weeks 
rather than months in other modalities even thought the sustained 
remission is hard to maintain. A similar response (75%) is seen with the 
administration of Anti-D antibody .The last two modalities the gamma 
globulin and the anti-D immunoglobulin saturates the complement 
receptors in the reticuloendothelial system thereby hindering the platelet 
destruction . 
  
 When these modalities have failed splenectomy has been tried with 
good results and these interventions have also transiently raised the CD4 
counts but they continue to be at a greater risk for fulminant opportunistic 
infections. Another alternative to splenectomy has been the low dose 
splenic irradiation which has in uncontrolled studies showed an acute 
response of 70%  and  sustained responses observed in over  40% of HIV-
1 patients77,78. 
Causes Of Cytopenias in a HIV patient . 
 The process of hematopoiesis is both an inducible and a 
constitutive one. The constitutive process is under the  control of the 
colony simulating factors whereas the inducible process is under the 
control of cytokines and interleukins that influence hematopoiesis in 
situations of altered demand.  
 The cytokines have the origin from the marrow blasts , endothelial 
cells,T Cells, and monocytes. The alterations in cytokines and the growth 
factors because of the HIV infection contribute to the hematopoietic 
abnormalities. Other contributory factors to the Cytopenias are 
opportunistic infections and neoplasm's and Myelosuppressive 
medications. 
 
  
Cytopenias due to Tumor, infection and Medications. 
 Lymphomas, Kaposi's sarcomas and Squamous Cell carcinoma are 
common to HIV and the bone marrow is found to be involved in one third 
of those with lymphomas it  is the non cleaved cell type which is frequent 
.Other causes are the Myelosuppressive medications which are used in 
HIV as it has been found that when these drugs are used in situations 
which have altered hematopoietic potential they potentiate the 
Myelosuppressive effect which are not commonly seen in non HIV 
patients. 
HIV and Various Colony stimulating factors. 
 The important factors that are used in HIV are the Granulocyte , 
Monocyte, granulocyte/monocyte colony stimulating factors and  the IL-3 
,stem cell factors and erythropoietin.  
 These glycoprotein's control the hematopoietic cells in the  cell 
maturation cycle from start to terminal maturation and the major role of 
the  cytokines is the suppression of the apoptosis . 
 The B and T lymphocytes and the Natural killer cells are the prime 
contributors of these colony stimulating factors. These cells are also the 
primary targets for the HIV as well and when these cells are infected they 
  
progressively decrease in numbers and thereby decreasing the colony 
stimulating factors. 
 The production of these factors increases during early infection and 
this attributes to the hyperrcellularity of the bone marrow seen at the 
earlier stages. The levels of IL -1 , TNF alpha and  interferon Gamma are 
low during the early stages as well. 
 As the disease advances the levels of the cytokines increase 
considerably and these in turn start to inhibit hematopoiesis rather than 
stimulating it and also the increasing cytokines alters the receptors on the 
target cells to make them less responsive to the stimulating growth 
factors.  
 Moreover inhibiting cytokines like the (TGF -Beta) are also found  
to be in increasing amounts and they also in turn inhibit hematopoiesis.  
 These negative factors of Hematopoiesis are produced by the HIV 
infection itself, with the Tat Protein being released from the monocytes 
stimulates the release of TNF -alpha, and the Nef protein that may be 
released from the infected cells induces the production  of IL-6. 
 All these are considered in the usage of the colony stimulating 
factors in treatment of the  Cytopenias with the exogenous administration 
  
of these factors often leads to the amelioration of the  effects on the 
Hematopoiesis.79-83 
 
  
 
Role of G CSF 
 HIV-1 patients who have been initiated on a HAART regimen and 
are exhibiting Cytopenias, the  G-CSF administration  substantially  
increases the concentration of CD4 +  and CD8 +  lymphocytes and  the 
NK cells. High dose administration causes modest elevation of 
monocytes and also causes  absolute increase in the neutrophil count. 
When  GM -CSF is given along with the concomitant ART the antiviral 
effects are also increased due to the raise  in the  active drug 
concentration within  the monocytes and this effect has been shown only 
with GM -CSF. 
Stem cell Factor (SCF,Kit Ligand
 Marrow Stromal cells produces a growth factor which 
myeloid ,lymphoid, and mast cell lineage and it acts in 
the other trophic factors. The SCF 
this correlates with the survival as well and when it is given to HIV
patients haematopoiesis
fashion without any alteration of the HIV expression.
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Interleukin -3  
 It is another factor that is  produced by the activated T cells and has 
also direct effects on all other  nucleated cells .Administration causes an  
increase in circulating granulocytes ,erythrocytes, and platelets. When the 
T cell numbers are decreasing in late stages it causes reduction in 
endogenous IL-3 which may contribute to myelosuppression and it has 
also been documented that suboptimal levels of IL-3 has a synergistic 
effect with other factors to counter the myelosuppression associated with 
HIV infections.  
 The mechanism that has been postulated is the prevention of 
apoptosis in the progenitor cells that is commonly seen in advanced HIV 
infection with reduced levels of growth factors. 
Interleukin -1 
 It is an acute phase reactant produced by the monocyte ,dendritic 
cells,lymphocytes,NK cells, fibroblasts and it induces the secretion of 
hematopoietic factors like G CSG, GMCSF and M CSF and also Il-6.If 
IL-1 secretion is continuously secreted it can lead to the increase 
production of TNF alpha that in turn suppresses the hematopoietic 
activity and it has also been found that the IL-1 increases with the 
progression of the HIV  infection. 
  
Interleukin - 2 
 It is a cytokine which acts as a growth factor for the lymphocytes 
and it induces the synthesis of Interferon Gamma which decrease 
haematopoiesis and also increases the HIV -1 replication . 
Interleukin-6 
 This cytokine is produced by the B and T cells, fibroblasts, 
eosinophils ,and vascular endothelial cells and it has also been directly 
and indirectly up regulated by the HIV-1 Tat Protein. IL -6 and IL - 3 acts 
synergistically to enhance haematopoiesis and IL-6 also up regulate the 
HIV-1 production by the infected cells and the enhanced T cell 
proliferation expands the HIV Infected cell pool . 
Interferons 
 This cytokine level increase with the progression of HIV infection 
and interferon -alpha inhibits marrow progenitor cells and this is by a 
supplementary effect by other cytokines which are stimulated directly by 
the interferons. Interferon -gamma up regulates the CXCR4 receptors on 
the bone marrow which is present of the maturing megakaryocytes and 
platelets and these being the co-receptors for HIV-1 causes a decrease in  
platelet counts with a rise in HIV viral load as occurring in late HIV 
infection. 
  
Tumor Necrosis Factor -Alpha. 
This cytokine is produced by the monocyte and macrophages and 
the Tat protein of HIV-1 infection activates the genes capable of 
producing TNF alpha. This cytokine is a both positive and  negative 
regulator of haematopoiesis. 
Transforming growth factor - Beta. 
This is a stimulatory agent particularly for the fibroblasts and is an 
inhibitor for hematopoietic proliferation and a reversible suppressive 
effect on the marrow progenitor cells. The levels of the cytokine also 
increases with HIV -1 infection and it is also increased by the Tat Protein 
of HIV and this also enhances the HIV -1 expression in infected cells . 
Coagulation abnormities associated with HIV. 
These abnormalities have been commonly noticed in HIV-1 
infection and in most of the situations and it has been attributed to the 
antiphospholipid antibodies which binds to cardiolipin,anionic 
phospholipids,beta-2 Glycoprotein -1 which predominantly inhibits 
coagulation and platelet aggregation. These antibodies are due to the 
abnormal immune responses as part of the HIV-1 infection and these 
titres vary with stage of the HIV infection and with the presence of 
opportunistic infections. It has been observed that the thromboembolic 
  
manifestations that occur as a part of these antibodies are less in HIV-1 
infected patients when compared with general population. 
It has also been observed that the protein -C and Protein- S levels 
are also significantly less in HIV-1 infected patients and these correlate 
with CD4 counts.  The  Protein S has been postulated to bind to the C4 
binding protein, and a subsequent increase in the protein-S levels with 
chronic  HIV infection results in a more compact  binding of Protein S 
and thereby less amounts are  available to prevent aberrant thrombotic 
even. There are also anti-Protein S antibodies which are seen in HIV-1 
infections which also contributes the lower levels .The levels of Heparin 
Co factor II is found to be lower in PLHIV and this level further 
decreases in advanced HIV infection. 
Several OIs have been associated with a Pro thrombotic State in 
PLHIV by mechanisms that restrict the expressions of Pro - Coagulant 
phospholipids to sites of vascular injury. The infections like CMV and 
HSV 1 & 2 have the ability to convert the vascular endothelial cells to a 
pro coagulative phenotype by altering the surface phospholipids which 
are active in the coagulation system. 
 
  
There have been documented evidences of increase in the Von 
willebrand factor with the increase in CD4 counts and also a decrease in 
the plasminogen activator levels correlates well with increasing HIV-1 
levels contributing to a prothrombotic stage. The hypoalbuminemia 
associated with the HIV infection also contributes to fibrinolytic defects 
.The incidence of Thrombotic thrombocytopenic Purpura is also more in 
HIV infected patients and the exact mechanism of this consumptive 
coagulopathy has not been studied yet and plasmapharesis with exchange 
has been proved effective to treat these patients.  
There also a hypergammaglobulinemia that has been documented 
and it has been due to a polyclonal B-cell activation and it is associated 
with inability to form antibodies when  exposed to new antigens. It causes 
rouleax on peripheral blood smear and it also parallels' generalized 
lymphadenopathy. Another interesting manifestations is the 
Hemophagocytic Syndrome which manifests with fever, 
Hepatospelnomegaly, and lymphadenopathy and Pancytopenia and shows 
the classical cells in the peripheral smear84-89. 
 
 
 
  
Bone Marrow findings in HIV. 
The bone marrow in HIV exhibits a multitude of morphologic 
aberrations. The typical bone marrow features are as follows.  
 
Hypercellularity of the marrow has been demonstrated as the most 
common finding in about a 50% of patients and is due to absolute 
hyperplasia of one or more non -lymphoid cell lineages.  
The Myeloid Erythroid ratio tends to be normal often and the 
marrow cellularity has been documented to correlate with neither the 
peripheral blood counts nor with the stage of the HIV disease. The 
hypocellularity of the marrow is quite a rare manifestation found in less 
than 5% of patients and is seen in more advanced stages of the infection 
as a fore runner to the atrophy and necrosis of the marrow which is seen 
in end stages of HIV-1 infection.  
  
It has been found that the dysplasia of one cell line is found in 
about 70% of patients and is similar to the myelodysplastic syndrome 
.The dysplasia of the granulocytic series with a characteristic 
vacuolization of the precursors is seen in both  the peripheral smear and 
marrow and is the most common one followed by the dysplasia of the 
erythrocytic  dysplasia in 50-60%  and  megakaryocytic series changes 
which is seen in about a third of patients and these changes increase in 
frequency with the presence of  coexistent opportunistic infections.  
Other manifestations that are noted are the iron over load in the 
maturing Erythroid cells and the incidence is around 60 %. The less 
common changes that are noted include the aggregation of lymphoid cells 
in about 20 % of patients and this occurs despite the presence of 
  
peripheral lymphopenia which can happen in HIV infection. 
 
There also occurs marrow fibrosis with advancing HIV infection 
and increase in marrow deposition of reticulin and this is seen with 
mycobacterium and fungal infection .There are also certain non specific 
changes which include histolytic erythrophagocytosis mild increase in the 
eosinophils and plasma cells90-92. 
 
 
 
 
  
METHODOLOGY 
Title Of the Study   
A study on Haematological Changes following  first Line HAART 
( Highly Active Anti retroviral Therapy) in Adult HIV -1 Infected 
Patients. 
Data Collection and the Source 
 HIV Patients admitted to Medical Units with Haematological 
changes after initiation of first line HAART during the study period. 
 HIV Patients Reviewed at the ART Centre at CMCH with 
Haematological changes   soon( day 15,1 month,6 month) after the 
initiation of first line  HAART during the study period 
Data collection Methods 
 All Adult HIV patients between the time period of Aug 2013 till 
July 2014 Who developed Haematological Changes Post First Line  
HAART initiation  was included in the study. 
This study includes the Detailed History, Clinical Features, 
Peripheral Smear Study, Automated CBC counts, and Bone Marrow of 
the HIV patients developing Haematological complications after 
initiation of the  HAART. 
  
 
Sampling Method. 
Prospective Cohort Study with Consecutive Sampling methods 
Sample Size : 52 Patients. 
Case Definitions 
Defined as per the National Aids Control Organisation (NACO ) 
HIV/ART  guidelines ( First line HAART, Anaemia < 10 gms % ) 
Inclusion Criteria  
    All adult HIV Patient who are initiated on First line HAART as per the 
NACO guidelines  at CMCH and who develop mild to severe 
haematological changes ( anaemia, thrombocytopenia, Pancytopenia  
Exclusion Criteria 
Patients on Myelosuppressive drugs ( other than Cotrimoxazole) 
Patients  who develop IRIS after initiation of HAART. 
Patients with  diagnosed haematological problems ( Malignancies, 
Hereditary  disorders, anaemia of Chronic Disease)  
Patients who are on treatment for both HIV and TB. 
Pregnant women and children with age  < 15   
  
Patients who are on treatment for HIV and CMV. 
Patients with both HIV  and Hep B and Hep C infections. 
Patients on Second Line HAART ,Patients with Renal Failure 
Patients with HIV -2 infections and Patients with poor adherence ( 
< 80%). 
Analysis:  All the Data were collected on to the Data collection sheet in 
an excel format and Analysis was  done using SPSS statistical Software 
and proportions were compared using Chi -Square test of Significance .A 
'p' value' of less than 0.05 was considered statistically significant. 
 
 
 
 
 
 
 
 
 
  
Characteristics of the study population 
 
52 Patients presented with anaemia and Cytopenias and were 
observed for a period of over 6 months .The anaemia was equally 
distributed among both sexes and most of them (90%)  were in the 
reproductive age group of 20 - 49 and  92 % of them were in  stage 3 or 
stage 4 disease when they were initiated on AZT based HAART.  
                 CHARACTERISTICS OF THE STUDY  POPULATION 
Parameter Male 
(n=26) 
Female 
(n=26) 
Total 
(52) 
Percentage
s (100) 
Age     
   0-19 0 1 1 1 
 20-29 2 10 12 23 
30-39 11 9 20 38 
40-49 10 4 14 27 
>50 3 2 5 9 
WHO Stage.     
Stage 2 3 1 4 8 
Stage 3 9 6 15 29 
Stage 4 14 19 33 63 
CD4 at Baseline     
>200 13 10 23 44 
50-199 12 13 25 48 
<50 1 3 4 7 
Type Of Anemia observed     
NORMOCYTIC 
NORMOCHROMIC 
2 7 9 17 
MICROCYTIC 
HYPOCHROMIC 
16 5 21 40 
NORMOCYTIC 
HYPOCHROMIC 
3 7 10 19 
MACROCYTIC 
HYPOCHROMIC 
5 7 12 23 
 
  
CHARACTERISTICS OF THE STUDY  POPULATION 
 
RBC COUNTS Male 
(n=26) 
Female 
(n=26) 
Total (52) Percentage
s (100) 
<2 13 7 20 38 
2-2.9 9 12 21 40 
3-3.9 4 5 9 17 
>4 0 2 2 3 
Hematocrit.     
<20 14 4 18 34 
20-29 7 11 18 34 
30-39 3 7 10 19 
>40 2 4 6 11 
Total Counts     
<1000 1 1 2 3 
1000-1999 2 4 6 11 
>4000 23 21 44 84 
Platelet counts     
0.5 4 8 12 23 
0.5-0.99 3 6 9 18 
1-1.49 1 0 1 1 
>1.5 18 12 30 58 
MCV     
<70 12 0 12 23 
70-79 4 5 9 17 
80-89 4 10 14 27 
90-99 3 6 9 17 
>100 3 5 8 15 
MCH.     
<25 15 11 26 50 
25-30 10 10 20 38 
>30 1 5 6 11 
 
Equal number of patients were found to have a CD4 counts above 
and below 200.  40 % of the study population had a Microcytic Hypo 
chromic anaemia and the other types were found to be equally distributed. 
RBC counts were found to be less than 2 million in about 38 % of 
  
patients and the Hematocrit was found to be less than 20 in about 34 % of 
patients.  
Mild Thrombocytopenia was noted in  42 % of the population and 
Moderate to Severe thrombocytopenia (<50,000) was observed in 23 %  
of them . MCV was low in 40 % of patients and MCH was low in 50 % 
and this equates well with the 40 %  incidence of Microcytic Hypo 
chromic  anaemia in this study population. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
2. Sex distribution amongst the Study population. 
 
 
Sex Frequency Percent 
Valid 
Percent 
Cumulative 
Percent 
 1.Male 26 50.0 50.0 50.0 
 
2.Female 26 50.0 50.0 100.0 
 
Total 52 100.0 100.0  
 
 
 
 
In the study population the sex distribution was evenly distributed 
with both males and females being represented in a cumulative 
percentage of 50 % which is pictorially depicted in the above picture. 
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3. AGE CATEGORISATION AND SEX DISTRIBUTION 
 Age Categorisation 
SEX 
                
Total 
  
1 . MALE 2. FEMALE 
            
Percent 
 0-19 0 1 1 1.9 
20-29 2 10 12 23.1 
30-39 11 9 20 38.5 
40-49 10 4 14 26.9 
>50 3 2 5 9.6 
                              Total 26 26 52 100.0 
 
 
Among the study population 88% of the patients were in the 
reproductive age group of 20-49 with the males representing by a slight 
higher margin in the age group category of 30-39 and 40-49 
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4. WHO STAGING AND SEX DISTRIUTION
 
  
WHO 
STAGE 
2 
3 
4 
Total 
 
 
  It was observed that 63.5 % of patients 
disease and there was no significant correlation (p
between the WHO stage and the sex distribution in the study population.
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SEX 
TotalMales Females 
3 1 
9 6 
14 19 
26 26 
P VALUE 0.308 
 
were in the stage 4 
- value of 0.308 )  
3 4
WHO STAGE
 
  
Percent 
4 7.7 
15 28.8 
33 63.5 
52 100.0 
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5. Frequency of Baseline CD4 counts and Sex distribution
                   CD4  at 
baseline 
 >200 
50-199 
<50 
                            Total
 
The base line CD4 among the study population was more than 200 
cells in 44.2 % and between (50
were 7.7 % .The p value was 0.489 and there was no significant 
relationship between these 2 variables in this study. 
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-199) it was 48.1 % and less than 50 cells 
 
Males
females
 
  
Percent 
23 44.2 
25 48.1 
4 7.7 
52 100.0 
6. Haemoglobin categorisation and Sex distribution
 
 
  HB Categorisation
 <6.9 
7-7.9 
8-8.9 
9-9.9 
>10 
                   Total 
 
                                                                           
 
 
 
 
The patients with severe anaemia 46.2 % and the majority of them 
were males and there was no significant correlation between the 
anaemia and the sex of 
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SEX 
Total Males Females 
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2 2 4 
6 5 11 
2 6 8 
1 4 5 
26 26 52 
P value - 0.249
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The most common type of Anaemia in the study was Microcytic 
Hypo chromic Anaemia found in 41% of population and when it was 
compared with sex there was a significant correlation (P Value of 
between the two variables. The second most common pattern 
Macrocytic Hypo chromic Anaemia in about 23 % of patients. Overall the 
Hypo chromic pattern was predominantly found among the study 
population. 
 
5. TYPE OF ANAEMIA AND SEX DISTRIBUTION
 
Type Of Anaemia
 1.Normocytic Normochromic An
2.Microcytic Hypochromic An
3. Normocytic Hypochrromic An
4  Macrocytic Hypochromic An
 
1.NNA
17%
2.MHA
3.NHA
19%
4. MAHA
23%
Type of anaemia and its 
distribution.
P VALUE   - 0.015 
 
Sex 
MALE FEMALES 
 2 7 
 16 5 
 3 7 
 5 7 
Total 26 26 
41%
0.015)  
was that of 
. 
Total 
9 
21 
10 
12 
52 
  
6. TIME TO DEVELOP ANAEMIA AND THE AGE 
DISTRIBUTION 
 Time to develop 
Anemia 
Age distribution 
Total 
  
                                                                                                                             
<20  20-29 
30-
39 
40-
49 
> 
50  Percentages 
 <60 days 0 5 6 4 2 17 32.7 
60-89 Days 1 5 9 8 1 24 46.2 
90-119 days 0 2 5 2 1 10 19.2 
>120 days 0 0 0 0 1 1 1.9 
          Total 1 12 20 14 5 52   
                                                       P value   - 0.386 
 
 
 
In The study 32.7 % developed anaemia in less than 60 days and 
46.2 % of people developed anaemia in 60- 89 days ,it was > 90 days in 
19.2 % of patients and there was no significance (p-.386) between the 
time to develop anaemia and the  age categorisation. 
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7. TIME TO DEVELOP ANAEMIA AND THE SEX 
DISTRIBUTION 
 Time to develop Anemia 
Sex                                                                  
Total Male females 
<60 days 9 8 17 
60-89 Days 9 15 24 
90-119 days 8 2 10 
>120 days 0 1 1 
Total 26 26 52 
 
P value    0 .104 
 
 
There was no statistical significance seen (p value of 0.104 ) 
between the time to develop anaemia and the  sex distribution. It was 
observed that the females developed the anaemia more between 60-90 
days but there  was no statistical significance correlation. 
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8.  TIME TO DEVELOP ANEMIA AND CD4 VALUES AT 
BASELINE. 
 
 
Time to develop Anaemia 
Baseline CD 4 Values 
Total >200 50-199 <50 
 <60 days 7 9 1 17 
60-89 Days 12 11 1 24 
90-119 days 4 4 2 10 
>120 days 0 1 0 1 
Total 23 25 4 52 
 
P VALUE - 0.675 
 
 
When Time to develop anaemia was compared with the CD4 
counts at baseline it  was observed that 78.8 %  of the study patients 
developed anaemia in less than 90 days and there was no significant 
correlation between the two variables. 
 
0
2
4
6
8
10
12
14
<60 days 60-89 Days 90-119 days >120 days
Time to develop Anemia
TIME TO DEVELOP ANEMIA   AND CD4 VALUES 
AT BASELINE.
Baseline CD 4 Values 
>200
Baseline CD 4 Values 50-
199
Baseline CD 4 Values <50
  
9. TIME TO DEVELOP ANEMIA AND WHO STAGING 
 
 
Time to develop Anemia 
WHO STAGE 
Total 2 3 4 
 <60 days 2 6 9 17 
60-89 Days 1 5 18 24 
90-119 days 1 4 5 10 
>120 days 0 0 1 1 
Total 4 15 33 52 
 
P.VALUE 0.718 
 
 
When the WHO staging at base line was compared with time to 
develop anaemia it was observed that 34.6% of patients in the stage 4 
category developed anaemia between 60-89 days and there was no 
significant correlation. 
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10. TIME TO DEVELOP ANEMIA AND THE TYPE OF ANEMIA 
 
Time to develop 
Anemia 
Type of anemia 
Total NNA MHA NHA MAHA 
 <60 days 3 7 5 2 17 
60-89 Days 6 7 3 8 24 
90-119 days 0 7 1 2 10 
>120 days 0 0 1 0 1 
Total 9 21 10 12 52 
            
P.VALUE 0.134 
\
 
When the type of anaemia and time to develop anaemia was 
compared it was observed that distribution of Microcytic hypo chromic 
anaemia was equally distributed between <60 ,60-89 ,and 90-119 days. 
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11. TIME TO DEVELOP ANEMIA AND HB % INCREASE AFTER ART 
SUBSTITUTION 
 
 Time to develop Anemia 
Hb % Increase after ART 
Substitution 
Total 
>50 
% 
50-
99% 100-149 >150 
 <60 days 10 7 0 0 17 
60-89 Days 13 7 2 2 24 
90-119 days 4 1 2 3 10 
>120 days 0 0 0 1 1 
Total 27 15 4 6 52 
 
P VALUE 0.028 
 
When the Hb rise after substitution was compared with the  time to 
develop anaemia there was  a (significant P value = 0.028 ) between the 
more than 50% rise and the time to development between 60-89 days. 
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14
>50 % 50-99% 100-149 % >150 %
Hb % Increase after ART Substitution
TIME TO DEVELOP ANEMIA AND HB % INCREASE 
AFTER ART SUBSTITUTION
Time to develop Anemia <60 
days
Time to develop Anemia 60-89 
Days
Time to develop Anemia 90-119 
days
Time to develop Anemia >120 
days
  
12. CD4 AT BASELINE AND PLATELET INCREASE % AFTER 
REGIMEN CHANGE 
 CD4  at 
baseline 
Platelet Increase % after regimen change 
Total >50 % 50-99% >150% 
 >200 7 5 11 23 
50-199 13 5 7 25 
<50 1 0 3 4 
Total 21 10 21 52 
 
P VALUE 0.294 
 
 
When the  platelet increase % after the regimen change was  correlated 
with the CD4  at baseline there was no significant correlation observed (P 
value of =0.294 ) between the comparing variables. 
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CD4 AT BASELINE AND PLATELET INCREASE % 
AFTER REGIMEN CHANGE
CD4  at baseline  >200
CD4  at baseline  50-199
CD4  at baseline  <50
13. TIME TO DEVELOP ANEMIA AND HEMATOCRIT 
 
 Time to develop 
Anemia 
 <60 days 
60-89 Days 
90-119 days 
>120 days 
Total 
When the Hematocrit rise was compared with the time to develop 
anaemia it was observed that there was a significant 
in the 60-89 days group .
 
0
2
4
6
8
10
12
14
16
<60 days 60-89 Days
Time to develop Anemia
 
INCREASE 
Hematocrit  Increase %. 
>50 % 50-99% >100 %
10 6 1 
15 7 2 
4 5 1 
0 0 1 
29 18 5 
 
    P VALUE 0.081 
 
rise (p value =0.081)
 
90-119 days >120 days
Hematocrit  Increase %. >50 %
Hematocrit  Increase %. 50
Hematocrit  Increase %. >100 %
Total  
17 
24 
10 
1 
52 
 
 
-99%
14. CD4 AT BASELINE AND THE PERCENTAGE OF 
 CD4  at baseline   
 >200 
50-199 
<50 
Total 
  
 
When the percentage increase
the base line CD4 counts there was no significant correlation between the  
comparing variables. 
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>50 %
Hematocrit  Increase %.
CD4 AT BASELINE AND THE PERCENTAGE OF 
 
HEMOCRIT INCREASE 
Hematocrit  Increase %. 
>50 %     50-99% 
    
>150% 
14 7 2 
12 10 3 
3 1 0 
29 18 5 
 
P VALUE = 0.804 
 
 
 of Hematocrit was compared with 
50-99% >150%
HEMOCRIT INCREASE
CD4  at baseline  >200
CD4  at baseline  50
CD4  at baseline  <50
Total 
23 
25 
4 
52 
 
-199
15. Hb INCREASE PERCENTAGE WHEN COMPARED 
WITH HAEMOGLOBIN AT BASELINE
 Hb Increase 
percentage 
 >50 % 
50-99% 
>100- 149% 
>150 % 
Total 
 
When the Haemoglobin percentage increase was compared with 
base  line Haemoglobin there  was a significant correlation (P=0.000) 
between the percentage rise of 50
less than 7. 
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14
less than 7 7- 7.9
Hemoglobin at baseline 
Hb INCREASE PERCENTAGE WHEN COMPARED 
WITH HAEMOGLOBIN AT BASELINE
 
 
Hemoglobin at baseline  
< 7   7- 7.9 8-8.9 9-9.9 
0 3 11 8 
14 1 0 0 
4 0 0 0 
6 0 0 0 
24 4 11 8 
 
P VALUE 0.000 
-99 % and the baseline Hb of 
8-8.9 9-9.9 > 10
Hb Increase percentage % >50 %
Hb Increase percentage % 50
Hb Increase percentage % >100
149%
Hb Increase percentage % >150 %
Total       >10 
5 27 
0 15 
0 4 
0 6 
5 52 
 
 
-99%
-
  
0
5
10
15
20
25
<0.5 0.5-0.99 1-1.49 >1.5
Platelet counts before change of regimen
PLATELET INCREASE % AFTER REGIMEN CHANGE AND PLATELET 
COUNTS BEFORE REGIMEN CHANGE
Platelet Increase %  after regimen 
change >50 %
Platelet Increase %  after regimen 
change 50-99%
Platelet Increase %  after regimen 
change >150%
16. PLATELET INCREASE % AFTER REGIMEN CHANGE AND 
PLATELET COUNTS BEFORE REGIMEN CHANGE 
 
 Platelet Increase %  
after regimen change 
Platelet counts before change of regimen 
                   
Total 
   
<0.5     0.5-0.99    1-1.49 
    
>1.5 
 >50 % 0 0 0 21 21 
50-99% 0 0 1 9 10 
>150% 12 9 0 0 21 
Total 12 9 1 30 52 
 
P VALUE 0.000 
 
When the platelet increase percentage from the base line was 
compared with its base line value following the substitution of the ART it 
was observed that there was a significant correlation (p= 0.000) of more 
than 50% increase and the baseline value of >1.5 lacs. 
  
Peripheral Smear Findings    
The Peripheral study mirrored with the findings found in the cell 
counts with  Hypo chromic  anaemia the most common findings in 83 % 
(43) of patients and normocytic anaemia in 17 % of the patients. 
Macrocytosis were found among 23  % of patients. Platelets were reduced 
in numbers in 12 (23 %) of patients and Pancytopenia in 7 patients (11%) 
who were subjected to bone marrow aspiration. 
Bone marrow findings     
Bone marrow aspiration for done in 7 of the 52 patients and the 
findings were similar in all of them. There was  hyper cellular bone 
marrow with a increased  myeloid Erythroid ratio in 6 of the patients. 
There was  no evidence of myelodysplastic changes and abnormal cells in 
the marrow. Bone marrow culture for did not reveal any opportunistic 
infections. In one of the patient there was a vacuolization of  the 
neutrophil precursors  with decrease in cells of the Erythroid lineage. In 
other patients Bone marrow aspiration was found unnecessary as there 
were no indications and in 22 patients did not consent for the invasive 
study.  
. 
 
  
DISCUSSION 
52 patients presented with anaemia with equal distribution among 
both sexes and all of them were found to be initiated on the AZT based 
regimen. This is in common with other studies which had shown AZT has 
the primary agent causing anaemia. 
The age in the study group ranged from 18-56 with 85 % in the 
reproductive age group which is similar to various other studies which 
had demonstrated the occurrence of the epidemic in the reproductive age 
group and there was no statistical significance noted with age and 
categorisation  and the incidence of haematological changes in this study. 
Besides Anaemia there were 13% incidence of Pancytopenia which 
is considerably low when compared  with studies done by Ellaurie et al 
and Castella et al in which the incidence was surprisingly higher at 
around 50 %.There was no significant correlation between the occurrence 
of  Pancytopenia and the baseline CD4 counts which was observed in 
other studies.  
The incidence of Thrombocytopenia was 42 % which was similar 
to the studies conducted by  Zon Li et al and Murphy Et al in which there 
was a 40% incidence was noted. It was also noted in the Multicenter  
AIDS cohort study the incidence of thrombocytopenia ranged from 13 - 
61 %. There was a significant increase in the rise from the base line of the  
  
platelet count  when it was compared with its base line value  following 
the substitution of the ART  and it was observed that there was a 
significant correlation (p= 0.000) of more than 50% increase and the 
baseline value of >1.5 lacs which is unique to this study.  
The platelet count normalised within a period of  6 months after  
substitution of the AZT based regimen  with Tenofovir based regimen. Of  
the patients who developed severe  thrombocytopenia all were found  to 
have CD4 counts distributed equally below and above 200.  
Signs and Symptoms. 
Among the clinical symptoms Fatigue and dyspnoea were found in 
34 % of patients and this was on par with other studies and among the 
patients who had fatigue and Dyspnoea ,the incidence of palpitation was 
61%.Diarrrohea was seen in 17 % of patients and Jaundice was not found  
in any one.  
There were 19 % of patients who had a high BP >140/90 and all of 
them were found to be above 40 age group and were on antihypertensive 
when the patient were started on ART. 
 
 
 
  
The incidence of anaemia and the type of Anaemia . 
All of the patients were on AZT before they developed anaemia 
and they were all transferred to a Tenofovir based regimen and they 
showed improvement in the haematological parameters. The percentage 
of severe anaemia <7 were 46.2 % in the study population and  which 
was in accordance with the  studies conducted by Aboulafia et al ( 70%) 
and when compared with the those with having CD4 <50  it was found in 
only 7% of the study population, which meant that the study population 
had  been started on ART before they reached a severe  immunological 
depletion of CD4 counts. 
 The most common type of Anaemia in the study was Microcytic 
Hypo chromic Anaemia found in 41% of population and when it was 
compared with sex there was a significant correlation (P Value of 0.015)  
between the two variables. The second most common pattern was that of 
Macrocytic Hypo chromic Anaemia in about 23 % of patients. Overall the 
Hypo chromic pattern was predominantly found among the study 
population.  
Another interesting observation that was made was the significant 
rise  in haemoglobin and Hematocrit after the initial drop due to AZT and 
it was observed especially in those patients who developed anaemia 
  
within 90 days of ART. This significant rise  in Hb and Hematocrit 
happened over a period of 6 months.  
The bone marrow findings did not bring about any significant 
correlation and they were on par with other studies .There was 
hyperrcellularity with increased myeloid Erythroid ration in 85 % of the 
patients who underwent bone marrow aspiration . 
 
 
 
 
 
 
 
 
 
 
 
                                           
  
                                         CONCLUSION 
1. There is a significant rise in Haemoglobin and the Hematocrit  
within a median time duration of 6 months after the change from AZT 
based  regimen. 
2. The Baseline CD4 counts, Age and Sex , did not significantly 
contribute  to the development of Cytopenias in this study but the AZT 
based regimen had a significant impact contributing to all the cases in the 
study population. 
 
 
 
 
                                                     
 
 
 
 
 
  
                                               SUMMARY 
1. The  age in the study group ranged from 18-56 with 85 % in the 
reproductive age group which is similar to various other studies. 
2. The percentage of severe anaemia <7 were 46.2 % in the study 
population and  which was in accordance with other studies. 
3. The most common type of Anaemia in the study was Microcytic Hypo 
chromic Anaemia found in 41% of population. 
4. Besides Anaemia there were 13% incidence of Pancytopenia which is 
considerably low and the incidence of Thrombocytopenia was 42 % 
which was similar to other studies. 
5. There was no significant correlation between the occurrence of  
Pancytopenia and the baseline CD4 counts which was observed in other 
studies 
6. The second most common pattern was that of Macrocytic Hypo 
chromic Anaemia in about 23 % of patients. 
7. Among the clinical symptoms Fatigue and dyspnoea were found in 34 
% of patients and this was on par with other studies. 
  
8. There was a significant rise  in haemoglobin and Hematocrit after the 
initial drop due to AZT and it was observed especially in those patients 
who developed anaemia within 90 days of ART. 
9. The platelet count normalised within a period of  6 months after  
substitution of the AZT based regimen  with Tenofovir based regimen. 
10. The bone marrow findings did not bring about any significant 
correlation and they were on par with other studies. 
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PROFORMA 
Name: 
Age:                                                          
Sex: 
Occupation:                                       
Address: 
Presenting illness: 
                             H/O Anaemia  following HAART initiation.                            
 Personal history: 
   H/O Alcohol intake 
                          Duration 
     Type  
     How often 
     Units of alcohol/day 
                       H/O Drug Intake ( ATT ,previous ART,2 and  line 
HAART, 
   Past history: 
               H/O  Myelosuppressive drugs ( other than Cotrimoxazole) 
                              IRIS after initiation of HAART. 
                               Haematological problems ( Malignancies, Hereditary  
disorders, anaemia of Chronic Disease)  
                              Treatment for both HIV and TB. 
                              HIV and CMV. 
                          HIV  and Hep B and Hep C infections. 
H/O  Second Line HAART ,Patients with Renal Failure 
H/O  HIV -2 infections  
  
H/O  poor adherence ( < 80%). 
Family history: 
                      H/O Systemic hypertension, Diabetes mellitus. 
   H/O Hereditary disorders in the family 
                      GENERAL EXAMINATION: 
                 Built: 
                 Height: 
                 Weight:        
                 Pallor, Icterus, Clubbing, Cyanosis 
       Lymphadenopathy, Pedal edema. 
Vital signs           PR:                                       RR: 
 
                          BP:                                               Temp: 
SYSTEMIC EXAMINATION: 
Cardio vascular system  
Respiratory system 
Central nervous system              
                                         Investigations. 
Complete Blood counts (Automated  ). 
CD 4 counts . 
Peripheral smear 
Bone marrow examination. 
                                
 
  
 
KEY TO MASTER CHART 
Symptoms  
 0 – No Symptoms 
 1 – Yes Symptoms  
MCH Category  
 0 to 25 = 1 
 25 – 30 = 2 
 30 = 3 
Sex   
1 = Male  
 2 = Female  
Anaemia 
 1 = Presence of Anaemia 
 0 = Absence of Anaemia 
MCV 
 < 80 = Microcytic 
 80-100 = Normocytic 
 100 =  Macrocytic 
ZLN  
 Zidovudine /  Lamivudine / Nevirapine 
BP < 140/80 = 0 = Normal  
       > 140/80 =1 =  High BP                      
 
  
xg;g[jy; gotk;; [ ; ;; [ ; ;; [ ; ; 
 
bgah;  : 
ghypdk; : 
Kfthp :     taJ  : 
  
muR nfhit kUj;Jtf; fy;Y}hpapy; bghJ kUj;Jt Jiwapy;  gl;l 
nkw;gog;g[ gapYk; khzth; kU. g[/f.,.uhkyp';fk; [ ; ;[ ; ;[ ; ;  mth;fs; 
nkw;bfhs;Sk;  "nfhaKj;J}h; kUj;Jt fy;Y}hp kUj;Jtkidapy;             ; ; ; ; ; ;; ; ; ; ; ;; ; ; ; ; ;
vr; I tp  nehapdhy; ghjpf;fg;gl;l nehahspfSf;F Kjy; epiy ; ; ; ; ; ; ;; ; ; ; ; ; ;; ; ; ; ; ; ; ART  
kUe;J bfhLg;gjpdhy; ,uj;j; ; ; ;; ; ; ;; ; ; ; j;jpy; cs;s mqf;fspy; Vw;gLk;; ; ; ; ; ; ;; ; ; ; ; ; ;; ; ; ; ; ; ; khWjy; ;;;
gw;wpa;;;  " Ma;tpy; bra;Kiw kw;Wk; midj;J tptu';fisa[k; nfl;Lf; 
bfhz;L vdJ re;njf';fis bjspt[gLj;jpf; bfhz;nld; vd;gij 
bjhptpj;Jf; bfhs;fpnwd;. 
ehd; ,e;j Ma;tpy; KG rk;kjj;Jld;/ Ra rpe;jida[lDk; 
fye;J bfhs;s rk;kjpf;fpnwd;. 
,e;j Ma;tpy; vd;Dila midj;J tpgu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy;  
Ml;nrgid ,y;iy vd;gij bjhptpj;Jf;bfhs;fpnwd;. ve;j neuj;jpy; 
me;j Ma;tpypUe;J ehd; tpyfpf; bfhs;s vdf;F chpik cz;L 
vd;gija[k; mwpntd;.  
 
,lk; :                     ifbahg;gk; / nuif 
ehs; : 
  
INFORMED CONSENT 
DEPARTMENT OF GENERAL MEDICINE 
Coimbatore Medical College, Coimbatore 
Principal investigator                      : Dr. Ramalingam. P.K. 
Research guide                                : Dr. Kumar Natarajan. M.D  
Organization                                    : Department of General Medicine  
Informed consent : I have been invited to participate in research Project 
titled ‘A STUDY ON HAEMATOLOGICAL CHANGES 
FOLLOWING  FIRST LINE HAART" I understand, it will be 
answering a set of questionnaire, undergo physical examination, 
investigations and appropriate treatment.  
I also give consent to utilize my personal details for study purpose and 
can be contacted if necessary.  
I am aware that I have the right to withdraw at any time which will not 
affect my medical care.  
Name of the participant: 
Signature: 
Date  
 
 
 
  
                      
 
ART ID NAME AGE Age Cat SEX CD4 Int CD4 Int CatCD4 OCUNTS AFTER 6 MONTHS OF ARTWHO STAGEFEVER ( 0=NO SYMPTOMS,1= YES)WEIGHT L SS ( 0 NO SYMPTOMS,1= YES)ANEMIA ( 0=NO SY PTOMS,1= YES)JAUNDICE ( 0=NO SYMPTOMS,1= YES)FATIGUE ( 0=NO SYMPTOMS,1= YES)
A2894 Lalitha 55 5 2 134 2 256 3 0 0 1 0 1
A2933 K.Prakash 40 4 1 273 1 2 1 1 1 0 1
A3137 Rabin Raj 33 3 1 232 1 3 0 0 1 0 1
A3186 Siddhik 33 3 1 230 1 4 1 1 1 0 1
A3225 Venkadapathy 55 5 1 188 2 4 0 0 1 0 1
A3329 Nagarani .R 36 3 1 219 1 4 0 0 1 0 1
A3424 Ranjith kumar 31 3 1 253 1 4 0 0 1 0 1
A3439 Latha.B 35 3 2 89 2 234 4 0 0 1 0 1
A3527 Gunasekaran.M 34 3 1 696 1 4 0 0 1 0 1
A3547 Muralidharan.N 47 4 1 182 2 4 0 0 1 0 1
A3590 Devi 27 2 2 175 2 345 4 0 0 1 0 1
A3866 Duraisamy 43 4 1 215 1 3 0 0 1 0 1
A3906 Selvaraj 34 3 1 198 2 247 4 0 0 1 0 1
A4044 Arumugam,R 38 3 1 299 1 3 0 0 1 0 1
A4069 Suresh 30 3 1 196 2 3 0 0 1 0 1
A4108 Aruchasamy 41 4 1 165 2 4 1 1 1 0 1
A4120 Chitra.A 29 2 2 196 2 4 0 0 1 0 1
A4144 Shanmugam 56 5 1 94 2 198 3 0 0 1 0 1
A4148
Krishnakumar.k
.r 44 4 1 202 1 456 2 1 1 1 0 1
A4152 Ashokan 45 4 1 40 3 246 4 0 0 1 0 1
A4153 Sheeba 38 3 2 194 2 289 4 1 1 1 0 1
A4163 Jegathambal 28 2 2 109 2 460 4 0 0 1 0 1
A4196 Ponnusamy. N 43 4 1 186 2 4 0 0 1 0 1
A4200 Thangamani 55 5 2 76 2 245 4 0 0 1 0 1
A4278 P.Selvi 25 2 1 244 1 2 0 0 1 0 1
A4322 Soundaraj.M 51 5 1 194 2 3 0 0 1 0 1
A4336 Ramathal.S 43 4 2 103 2 345 4 0 0 1 0 1
A4340 Jaithal.K 13 1 2 51 2 134 4 0 0 1 0 1
A4354 Sudha 29 2 2 65 2 265 4 1 1 1 0 1
A4396 Saraswathy 30 3 2 68 2 278 4 1 1 1 0 1
A4402 Mary 40 4 2 340 1 408 2 1 1 1 0 0
A4405 Saraswathi 30 3 2 243 1 340 4 1 1 1 0 0
A4407 Parameswari.K 28 2 2 272 1 4 1 1 1 0 1
A4447 Indra.R 42 4 2 291 1 403 4 1 1 1 0 0
A4450 Indhirani. P 29 2 2 314 1 345 4 1 1 1 0 0
A4472 Krishnaveni.M 30 3 2 292 1 4 1 1 1 0 1
A4477 Geetha.R 28 2 2 301 1 3 1 1 1 0 1
A4539 Gomathy.K 37 3 2 63 2 200 3 0 0 1 1 0
A4585 Raj. D 48 4 1 276 1 3 1 1 1 0 0
A4591 Vimalraj.P 32 3 1 192 2 4 0 0 1 0 0
A4638 Radha 34 3 2 48 3 202 3 1 1 1 0 0
A4648 Prithivi.M 49 4 1 329 1 4 0 0 1 1 0
A4651 Vijayalakshmi. R 35 3 2 124 2 246 3 1 1 1 0 1
A4671 Chithra.C 24 2 2 43 3 290 4 0 0 1 0 0
A4675
Balasubramani
am 40 4 1 167 2 3 1 1 1 0 1
A4704 Radhika.A     40 4 2 328 1 4 0 0 1 0 0
A4726 Kousalya.N 35 3 2 310 1 4 1 1 1 0 1
A4829 Sathishkumar.C 34 3 1 115 2 240 3 0 0 1 0 0
A4849 Chinnasamy. A 22 2 1 233 1 4 1 1 1 0 1
A4868 Kadeswari 25 2 2 295 1 3 0 0 1 0 1
A4872 Rajendran.P 37 3 1 135 2 4 0 0 1 0 1
A5148 BEENA.J 24 2 2 39 3 309 4 0 0 1 0 0
0 1
20 2 0 3
30 3 50 2
40 4 200 1
50 5
  
 
 
ART ID NAME DYSPNEA ( 0=NO SYMPTOMS,1= YES)ANOREXIA ( 0=NO SYMPTOMS,1= YES)C UGH ( 0=N  SYMPTOMS,1= YES)DIARRHOEA ( 0=NO SYMPTOMS,1= YES)PALPITATION ( 0=NO SYMPTOMS,1= YES)Pulse rate BP( 0= NORMAL,1= > 140/90)TEMPERATURE ( 0= NORMAL ,1= FEBRILE)PALLOR ( 0=NO PALOR,1= PALOR)CYANOSIS ( 0 NO ,1= YES)
A2894 Lalitha 1 1 0 0 0 90 1 0 1 0
A2933 K.Prakash 1 1 0 0 1 98 0 0 1 0
A3137 Rabin Raj 1 1 0 0 0 96 0 0 1 0
A3186 Siddhik 1 0 0 0 1 96 0 0 1 0
A3225 Venkadapathy 1 0 1 0 1 88 1 0 1 0
A3329 Nagarani .R 0 1 0 0 0 75 0 0 1 0
A3424 Ranjith kumar 0 0 0 0 0 88 0 1 0
A3439 Latha.B 0 1 0 0 0 80 0 0 1 0
A3527 Gunasekaran.M 0 0 0 0 1 110 0 0 1 0
A3547 Muralidharan.N 1 1 0 0 0 74 1 0 1 0
A3590 Devi 1 1 0 0 0 88 0 0 1 0
A3866 Duraisamy 0 0 0 1 0 78 1 0
A3906 Selvaraj 1 0 1 0 0 94 0 0 1 0
A4044 Arumugam,R 0 1 0 1 1 100 0 1 0
A4069 Suresh 0 1 0 1 0 70 1 1 0
A4108 Aruchasamy 1 0 0 0 1 88 0 0 1 0
A4120 Chitra.A 0 0 1 1 0 80 0 1 0
A4144 Shanmugam 1 0 0 0 0 94 1 0 1 0
A4148
Krishnakumar.k
.r 1 1 1 1 1 104 1 0 1 0
A4152 Ashokan 1 0 0 0 1 90 1 0 1 0
A4153 Sheeba 0 0 1 0 0 70 0 0 0 0
A4163 Jegathambal 0 1 0 0 0 72 0 0 0 0
A4196 Ponnusamy. N 1 0 0 0 1 108 0 0 0 0
A4200 Thangamani 1 1 0 0 1 98 0 0 0 0
A4278 P.Selvi 0 0 1 0 0 78 0 0 0 0
A4322 Soundaraj.M 0 0 1 0 0 89 1 0 1 0
A4336 Ramathal.S 1 1 0 0 1 100 0 0 0 0
A4340 Jaithal.K 0 0 0 0 0 74 0 0 0 0
A4354 Sudha 0 0 1 1 0 76 0 0 0 0
A4396 Saraswathy 1 1 0 1 0 80 0 0 0 0
A4402 Mary 0 0 0 0 0 88 0 0 0 0
A4405 Saraswathi 0 0 0 0 0 80 0 0 0 0
A4407 Parameswari.K 1 1 0 0 0 90 0 0 0 0
A4447 Indra.R 0 0 0 0 0 92 1 0 0 0
A4450 Indhirani. P 0 1 0 0 0 68 0 0 0 0
A4472 Krishnaveni.M 0 0 1 0 0 78 0 0 0 0
A4477 Geetha.R 0 0 0 0 0 64 0 0 0 0
A4539 Gomathy.K 0 0 0 0 0 90 0 0 0 0
A4585 Raj. D 0 1 0 0 0 78 0 0 0 0
A4591 Vimalraj.P 0 0 0 0 0 76 0 0 0 0
A4638 Radha 0 1 0 0 0 86 0 0 0 0
A4648 Prithivi.M 0 0 0 1 0 88 0 0 0 0
A4651 Vijayalakshmi. R 0 1 1 0 0 88 0 0 0 0
A4671 Chithra.C 0 0 0 0 0 70 0 0 0 0
A4675
Balasubramani
am 0 0 0 0 0 76 0 0 0
A4704 Radhika.A     0 0 0 0 0 74 0 0 0 0
A4726 Kousalya.N 1 1 0 0 0 68 0 0 0 0
A4829 Sathishkumar.C 0 0 0 0 0 90 1 0 0 0
A4849 Chinnasamy. A 0 1 1 0 0 78 0 0 0
A4868 Kadeswari 0 0 0 0 0 90 0 0 0
A4872 Rajendran.P 0 1 1 1 0 88 0 0 0
A5148 BEENA.J 0 0 0 0 0 80 0 0 0 0
  
 
 
ART ID NAME EMACIATION( 0- NO,1= YES)EDEMA ( 0= NO,1=YES)O THRUSH ( 0=NO,1= YES) PETECHEIAE( 0= NO,1=YES)CVS ( 0=NO SYMPTOMS,1= YES)RS ( 0=NO S MPTOMS,1= YES)PA ( 0=NO SYMPTOMS,1= YES)CNS ( 0=NO SYMPTOMS,1= YES)HB HB Cat
A2894 Lalitha 1 1 0 0 0 0 0 0 6 1
A2933 K.Prakash 1 1 1 1 0 0 0 0 5 1
A3137 Rabin Raj 0 1 1 0 0 0 0 0 8 3
A3186 Siddhik 0 0 0 0 0 0 0 0 6 1
A3225 Venkadapathy 1 0 1 0 0 0 0 0 8 3
A3329 Nagarani .R 0 0 0 0 0 0 0 0 5 1
A3424 Ranjith kumar 0 0 0 0 0 0 0 0 7 2
A3439 Latha.B 0 0 0 0 0 0 0 0 8 3
A3527 Gunasekaran.M 0 1 0 0 0 0 0 0 4 1
A3547 Muralidharan.N 0 0 0 0 0 0 0 0 8 3
A3590 Devi 1 0 0 1 0 0 0 0 6 1
A3866 Duraisamy 0 0 0 0 7 2
A3906 Selvaraj 1 1 1 0 0 0 0 0 6 1
A4044 Arumugam,R 0 1 0 0 3 1
A4069 Suresh 0 0 0 0 5 1
A4108 Aruchasamy 0 1 0 0 0 0 0 0 4 1
A4120 Chitra.A 1 0 6 1
A4144 Shanmugam 1 1 1 1 0 0 0 0 4 1
A4148 Krishnakumar.k.r 0 1 0 0 4 1
A4152 Ashokan 1 0 0 0 0 0 0 0 5 1
A4153 Sheeba 0 0 0 0 0 0 0 6 1
A4163 Jegathambal 0 0 0 0 0 0 0 0 8 3
A4196 Ponnusamy. N 0 1 0 0 0 0 0 0 2 1
A4200 Thangamani 1 1 0 0 0 0 0 0 4 1
A4278 P.Selvi 0 0 0 0 0 0 0 0 6 1
A4322 Soundaraj.M 1 0 1 0 0 0 0 0 6 1
A4336 Ramathal.S 0 1 0 0 4 1
A4340 Jaithal.K 0 0 0 0 0 0 0 0 5 1
A4354 Sudha 1 0 1 0 7 2
A4396 Saraswathy 0 1 0 0 0 0 0 0 10.1 5
A4402 Mary 0 0 0 1 10 5
A4405 Saraswathi 0 0 0 0 0 0 0 0 9.1 4
A4407 Parameswari.K 0 1 0 0 0 0 0 0 9.3 4
A4447 Indra.R 0 0 0 0 0 0 0 0 9.4 4
A4450 Indhirani. P 0 0 0 1 0 0 0 0 10.3 5
A4472 Krishnaveni.M 1 0 0 0 0 0 0 0 8 3
A4477 Geetha.R 0 0 1 0 0 0 0 0 6 1
A4539 Gomathy.K 0 0 0 1 0 0 0 0 8.5 3
A4585 Raj. D 0 0 0 0 10.4 5
A4591 Vimalraj.P 0 0 0 0 0 0 0 0 9 4
A4638 Radha 0 0 0 0 9.4 4
A4648 Prithivi.M 0 0 0 0 9.3 4
A4651 Vijayalakshmi. R 0 0 0 0 0 0 0 0 7 2
A4671 Chithra.C 0 0 0 0 9.8 4
A4675 Balasubramaniam 0 0 1 0 0 0 0 0 5 1
A4704 Radhika.A     0 0 0 1 8.9 3
A4726 Kousalya.N 0 1 0 1 0 0 0 0 9.8 4
A4829 Sathishkumar.C 0 0 0 0 0 0 0 0 8.6 3
A4849 Chinnasamy. A 0 0 0 0 0 0 0 0 8 3
A4868 Kadeswari 0 0 1 0 0 0 0 0 6 1
A4872 Rajendran.P 1 0 0 0 0 0 0 0 8 3
A5148 BEENA.J 0 0 0 0 1 0 0 0 10.1 5
0 1
7 2
8 3
9 4
10 5
  
ART ID NAME HEMATOCRIT Hematocrit Cat TC TC cat NEUTROPIL COUNT %Abs Neut Abs Neut Cat LYMPHOCYTE COUNT %Abs Lymph Abs Lymph Cat
A2894 Lalitha 22 2 1500 2 60 900 2 16 240
A2933 K.Prakash 18 1 800 1 54 432 1 18 144
A3137 Rabin Raj 14 1 1200 2 70 840 2 21 252
A3186 Siddhik 23 2 6800 4 72 4896 4 17 1156
A3225 Venkadapathy 24 2 9200 4 80 7360 4 12 1104
A3329 Nagarani .R 16 1 5800 4 82 4756 4 19 1102
A3424 Ranjith kumar 18 1 11900 4 82 9758 4 14 1666
A3439 Latha.B 26 2 10900 4 79 8611 4 20 2180
A3527 Gunasekaran.M 22 2 9800 4 80 7840 4 12 1176
A3547 Muralidharan.N 18 1 10900 4 90 9810 4 8 872
A3590 Devi 21 2 1300 2 61 793 2 21 273
A3866 Duraisamy 17 1 6700 4 55 3685 4 19 1273
A3906 Selvaraj 20 2 12000 4 82 9840 4 19 2280
A4044 Arumugam,R 14 1 9900 4 82 8118 4 14 1386
A4069 Suresh 16 1 9800 4 80 7840 4 7 686
A4108 Aruchasamy 16 1 11000 4 80 8800 4 12 1320
A4120 Chitra.A 19 1 6800 4 90 6120 4 8 544
A4144 Shanmugam 16 1 1700 2 61 1037 3 21 357
A4148 Krishnakumar.k.r 16 1 8800 4 85 7480 4 9 792
A4152 Ashokan 20 2 9800 4 84 8232 4 12 1176
A4153 Sheeba 18 1 11000 4 72 7920 4 17 1870
A4163 Jegathambal 24 2 6800 4 80 5440 4 12 816
A4196 Ponnusamy. N 16 1 9200 4 82 7544 4 19 1748
A4200 Thangamani 16 1 9900 4 80 7920 4 12 1188
A4278 P.Selvi 16 1 11000 4 90 9900 4 8 880
A4322 Soundaraj.M 18 1 6800 4 60 4080 4 20 1360
A4336 Ramathal.S 14 1 9800 4 63 6174 4 13 1274
A4340 Jaithal.K 20 2 9200 4 82 7544 4 19 1748
A4354 Sudha 22 2 9900 4 61 6039 4 21 2079
A4396 Saraswathy 30 3 11000 4 85 9350 4 9 990
A4402 Mary 34 3 6800 4 84 5712 4 12 816
A4405 Saraswathi 36 3 9800 4 72 7056 4 17 1666
A4407 Parameswari.K 34.2 3 8900 4 74 6586 4 11 979
A4447 Indra.R 42 4 1200 2 50 600 2 39 468
A4450 Indhirani. P 29 2 800 1 88 704 2 12 96
A4472 Krishnaveni.M 22 2 6800 4 90 6120 4 8 544
A4477 Geetha.R 24 2 9200 4 78 7176 4 12 1104
A4539 Gomathy.K 43 4 9900 4 61 6039 4 37 3663
A4585 Raj. D 47 4 11000 4 53 5830 4 26 2860
A4591 Vimalraj.P 32 3 6800 4 60 4080 4 10 680
A4638 Radha 38 3 9800 4 82 8036 4 9 882
A4648 Prithivi.M 41 4 10800 4 58 6264 4 36 3888
A4651 Vijayalakshmi. R 26 2 7500 4 60 4500 4 22 1650
A4671 Chithra.C 30 3 9800 4 67 6566 4 19 1862
A4675 Balasubramaniam 26 2 6800 4 59 4012 4 13 884
A4704 Radhika.A     43 4 6900 4 64 4416 4 15 1035
A4726 Kousalya.N 44 4 1500 2 86 1290 3 13 195
A4829 Sathishkumar.C 38 3 8800 4 76 6688 4 10 880
A4849 Chinnasamy. A 28 2 6400 4 60 3840 4 20 1280
A4868 Kadeswari 28 2 8400 4 88 7392 4 9 756
A4872 Rajendran.P 30 3 9990 4 89 8891.1 4 8 799.2
A5148 BEENA.J 30 3 6900 4 80 5520 4 14 966
0 1 0 1 0 1 0
20 2 1000 2 500 2 500
30 3 2000 3 1000 3 1000
40 4 4000 4 1500 4 1500
  
ART ID NAME RBC COUNT RBC Count Cat PATELET COUNTSPlatelet Cat time Time Cat  MCV MCv Cat  MCH
A2894 Lalitha 1.9 1 0.4 1 30 1 74 2 26
A2933 K.Prakash 1.6 1 0.2 1 40 1 72 2 24
A3137 Rabin Raj 1.7 1 0.5 2 45 1 68 1 23
A3186 Siddhik 2 2 2.6 4 60 2 60 1 22
A3225 Venkadapathy 2.2 2 2.9 4 73 2 58 1 24
A3329 Nagarani .R 1.9 1 4 4 78 2 98 4 24
A3424 Ranjith kumar 2.3 2 3.5 4 74 2 107 5 24
A3439 Latha.B 2 2 5.6 4 80 2 80 3 28
A3527 Gunasekaran.M 1.8 1 2.4 4 90 3 56 1 25
A3547 Muralidharan.N 1.9 1 1.9 4 30 1 62 1 26
A3590 Devi 2.1 2 0.1 1 32 1 80 3 24
A3866 Duraisamy 2.1 2 3.6 4 46 1 108 5 25
A3906 Selvaraj 1.8 1 2.4 4 78 2 60 1 25
A4044 Arumugam,R 1.4 1 3.5 4 90 3 54 1 24
A4069 Suresh 1.5 1 3.6 4 92 3 98 4 26
A4108 Aruchasamy 1.9 1 2.9 4 80 2 62 1 22
A4120 Chitra.A 1.8 1 2.9 4 24 1 80 3 24
A4144 Shanmugam 1.6 1 0.6 2 92 3 64 1 24
A4148 Krishnakumar.k.r 2.4 2 1 3 108 3 78 2 24
A4152 Ashokan 2.2 2 3.8 4 90 3 88 3 26
A4153 Sheeba 2.7 2 2.9 4 80 2 86 3 28
A4163 Jegathambal 2.3 2 3 4 95 3 102 5 22
A4196 Ponnusamy. N 2.7 2 4 4 80 2 100 5 26
A4200 Thangamani 1.9 1 3.2 4 120 4 90 4 22
A4278 P.Selvi 3.2 3 1.7 4 49 1 92 4 28
A4322 Soundaraj.M 3.4 3 2.7 4 30 1 60 1 22
A4336 Ramathal.S 1.8 1 6.2 4 62 2 88 3 22
A4340 Jaithal.K 2 2 3.5 4 68 2 98 4 26
A4354 Sudha 2.6 2 1.8 4 82 2 101 5 25
A4396 Saraswathy 2.3 2 0.4 1 20 1 88 3 28
A4402 Mary 3.4 3 0.2 1 60 2 89 3 31
A4405 Saraswathi 3.1 3 0.5 2 86 2 92 4 29
A4407 Parameswari.K 2.9 2 0.45 1 48 1 94 4 33
A4447 Indra.R 3 3 0.6 2 60 2 78 2 25
A4450 Indhirani. P 4.2 4 0.1 1 78 2 82 3 32
A4472 Krishnaveni.M 1.9 1 1.6 4 84 2 111 5 24
A4477 Geetha.R 1.8 1 4 4 88 2 80 3 24
A4539 Gomathy.K 2.3 2 0.04 1 68 2 83 3 31
A4585 Raj. D 3.6 3 0.19 1 60 2 80 3 29
A4591 Vimalraj.P 1.8 1 0.88 2 92 3 77 2 24
A4638 Radha 2 2 0.45 1 90 3 76 2 26
A4648 Prithivi.M 3.6 3 0.48 1 40 1 79 2 25
A4651 Vijayalakshmi. R 1.9 1 2.9 4 43 1 70 2 22
A4671 Chithra.C 4.3 4 0.75 2 60 2 99 4 22
A4675 Balasubramaniam 1.8 1 2.4 4 62 2 58 1 20
A4704 Radhika.A     3.8 3 0.92 2 66 2 106 5 24
A4726 Kousalya.N 3.4 3 0.6 2 43 1 102 5 26
A4829 Sathishkumar.C 2.2 2 0.35 1 49 1 88 3 35
A4849 Chinnasamy. A 1.5 1 2.3 4 90 3 52 1 18
A4868 Kadeswari 2.2 2 1.7 4 88 2 78 2 24
A4872 Rajendran.P 2.8 2 2.5 4 58 1 86 3 24
A5148 BEENA.J 2.6 2 0.88 2 34 1 95 4 34
0 1 0 1 0 1 0 1 0
2 2 0.5 2 60 2 70 2 25
3 3 1 3 90 3 80 3 30
4 4 1.5 4 120 4 90 4
100 5
  
  
ART ID NAME MCH Cat  type of anemia( NNA=1,MHA=2,NHA=3,MAHA=4)ART REGI EN MCV value after change of regimenHb 2 d Hb Inc Hb Inc % Hb Inc % Cat Hct 2nd Hct Inc
A2894 Lalitha 2 2 ZLN 98 10.2 4.2 70 2 28 6
A2933 K.Prakash 1 2 ZLN 93 9 4 80 2 29 11
A3137 Rabin Raj 1 2 ZLN 81 10 2 25 1 30 16
A3186 Siddhik 1 2 ZLN 84 9 3 50 2 32 9
A3225 Venkadapathy 1 2 ZLN 81 11 3 37.5 1 26 2
A3329 Nagarani .R 1 4 ZLN 80 9 4 80 2 28 12
A3424 Ranjith kumar 1 4 ZLE 110 10 3 42.85714286 1 32 14
A3439 Latha.B 2 1 ZLN 102 9.8 1.8 22.5 1 40 14
A3527 Gunasekaran.M 2 2 ZLN 92 9.8 5.8 145 3 42 20
A3547 Muralidharan.N 2 2 ZLN 84 11 3 37.5 1 29 11
A3590 Devi 1 3 ZLN 104 10 4 66.66666667 2 40 19
A3866 Duraisamy 2 4 ZLN 106 9.9 2.9 41.42857143 1 25 8
A3906 Selvaraj 2 2 ZLN 96 9.8 3.8 63.33333333 2 24 4
A4044 Arumugam,R 1 2 ZLN 92 9.2 6.2 206.6666667 4 30 16
A4069 Suresh 2 4 ZLE 100 9.1 4.1 82 2 26 10
A4108 Aruchasamy 1 2 ZLN 90 8.9 4.9 122.5 3 24 8
A4120 Chitra.A 1 3 ZLN 89 10.4 4.4 73.33333333 2 23 4
A4144 Shanmugam 1 2 ZLN 102 10.4 6.4 160 4 26 10
A4148 Krishnakumar.k.r 1 2 ZLN 110 11 7 175 4 29 13
A4152 Ashokan 2 3 ZLN 99 10.2 5.2 104 3 32 12
A4153 Sheeba 2 3 ZLN 102 9.8 3.8 63.33333333 2 31 13
A4163 Jegathambal 1 4 ZLN 103 11 3 37.5 1 26 2
A4196 Ponnusamy. N 2 4 ZLE 102 10 8 400 4 36 20
A4200 Thangamani 1 3 ZLN 118 10 6 150 4 34 18
A4278 P.Selvi 2 3 ZLN 91 11 5 83.33333333 2 28 12
A4322 Soundaraj.M 1 2 ZLE 90 11.4 5.4 90 2 29 11
A4336 Ramathal.S 1 3 ZLN 89 11.1 7.1 177.5 4 34 20
A4340 Jaithal.K 2 4 ZLE 96 10.2 5.2 104 3 37 17
A4354 Sudha 2 4 ZLN 106 10.1 3.1 44.28571429 1 32 10
A4396 Saraswathy 2 3 ZLN 98 12 1.9 18.81188119 1 36 6
A4402 Mary 3 1 ZLN 94 13.2 3.2 32 1 38 4
A4405 Saraswathi 2 1 ZLN 90 12.3 3.2 35.16483516 1 43 7
A4407 Parameswari.K 3 1 ZLN 94 13.2 3.9 41.93548387 1 42 7.8
A4447 Indra.R 2 2 ZLN 92 1.5 -7.9 -84.04255319 1 43 1
A4450 Indhirani. P 3 1 ZLN 88 10.8 0.5 4.854368932 1 34 5
A4472 Krishnaveni.M 1 4 ZLN 102 10.3 2.3 28.75 1 37 15
A4477 Geetha.R 1 3 ZLN 84 10.1 4.1 68.33333333 2 34 10
A4539 Gomathy.K 3 1 ZLN 94 11.9 3.4 40 1 42 -1
A4585 Raj. D 2 1 ZLN 98 11 0.6 5.769230769 1 45 -2
A4591 Vimalraj.P 1 2 ZLN 102 11.4 2.4 26.66666667 1 33 1
A4638 Radha 2 2 ZLN 100 12 2.6 27.65957447 1 36 -2
A4648 Prithivi.M 2 2 ZLN 96 13.4 4.1 44.08602151 1 45 4
A4651 Vijayalakshmi. R 1 2 ZLN 88 13.4 6.4 91.42857143 2 43 17
A4671 Chithra.C 1 4 ZLN 114 13 3.2 32.65306122 1 26 -4
A4675 Balasubramaniam 1 2 ZLN 82 9.3 4.3 86 2 28 2
A4704 Radhika.A     1 4 ZLN 108 11.3 2.4 26.96629213 1 42 -1
A4726 Kousalya.N 2 4 ZLN 106 9.5 -0.3 -3.06122449 1 39 -5
A4829 Sathishkumar.C 3 1 ZLN 90 10 1.4 16.27906977 1 41 3
A4849 Chinnasamy. A 1 2 ZLN 78 11 3 37.5 1 33 5
A4868 Kadeswari 1 2 ZLN 89 10.2 4.2 70 2 35 7
A4872 Rajendran.P 1 3 ZLN 88 11.3 3.3 41.25 1 38 8
A5148 BEENA.J 3 1 ZLN 98 10.7 0.6 5.940594059 1 41 11
67.88814042
1 0 1
2 50 2
3 100 3
150 4
  
 
 
 
 
ART ID NAME Hct Inc % Hct Inc% Cat platelet 2nd Platelet Inc Platelet Inc % Platelet Inc % CatTC 2nd Tc Inc TC Inc % TC Inc% Cat
A2894 Lalitha 27.27272727 1 1.4 1 250 4 6900 5400 360 4
A2933 K.Prakash 61.11111111 2 2.4 2.2 1100 4 7800 7000 875 4
A3137 Rabin Raj 114.2857143 3 1.5 1 200 4 6700 5500 458.3333333 4
A3186 Siddhik 39.13043478 1 2.7 0.1 3.846153846 1 9600 2800 41.17647059 1
A3225 Venkadapathy 8.333333333 1 2.9 0 0 1 9800 600 6.52173913 1
A3329 Nagarani .R 75 2 3.8 -0.2 -5 1 6700 900 15.51724138 1
A3424 Ranjith kumar 77.77777778 2 5.6 2.1 60 2 9800 -2100 -17.64705882 1
A3439 Latha.B 53.84615385 2 4.5 -1.1 -19.64285714 1 10000 -900 -8.256880734 1
A3527 Gunasekaran.M 90.90909091 2 4.7 2.3 95.83333333 2 11000 1200 12.24489796 1
A3547 Muralidharan.N 61.11111111 2 3.6 1.7 89.47368421 2 13000 2100 19.26605505 1
A3590 Devi 90.47619048 2 1.6 1.5 1500 4 5600 4300 330.7692308 4
A3866 Duraisamy 47.05882353 1 4.5 0.9 25 1 6900 200 2.985074627 1
A3906 Selvaraj 20 1 3.6 1.2 50 2 10900 -1100 -9.166666667 1
A4044 Arumugam,R 114.2857143 3 4.2 0.7 20 1 11000 1100 11.11111111 1
A4069 Suresh 62.5 2 2.3 -1.3 -36.11111111 1 9000 -800 -8.163265306 1
A4108 Aruchasamy 50 2 3.5 0.6 20.68965517 1 13000 2000 18.18181818 1
A4120 Chitra.A 21.05263158 1 4.3 1.4 48.27586207 1 6700 -100 -1.470588235 1
A4144 Shanmugam 62.5 2 2.1 1.5 250 4 4500 2800 164.7058824 4
A4148 Krishnakumar.k.r 81.25 2 1.9 0.9 90 2 6900 -1900 -21.59090909 1
A4152 Ashokan 60 2 3.9 0.1 2.631578947 1 9200 -600 -6.12244898 1
A4153 Sheeba 72.22222222 2 4.5 1.6 55.17241379 2 10500 -500 -4.545454545 1
A4163 Jegathambal 8.333333333 1 5.6 2.6 86.66666667 2 7800 1000 14.70588235 1
A4196 Ponnusamy. N 125 3 5.9 1.9 47.5 1 8800 -400 -4.347826087 1
A4200 Thangamani 112.5 3 4.5 1.3 40.625 1 7800 -2100 -21.21212121 1
A4278 P.Selvi 75 2 3.2 1.5 88.23529412 2 6500 -4500 -40.90909091 1
A4322 Soundaraj.M 61.11111111 2 4 1.3 48.14814815 1 7800 1000 14.70588235 1
A4336 Ramathal.S 142.8571429 3 5.6 -0.6 -9.677419355 1 8900 -900 -9.183673469 1
A4340 Jaithal.K 85 2 5 1.5 42.85714286 1 9900 700 7.608695652 1
A4354 Sudha 45.45454545 1 2.3 0.5 27.77777778 1 9000 -900 -9.090909091 1
A4396 Saraswathy 20 1 4.5 4.1 1025 4 9800 -1200 -10.90909091 1
A4402 Mary 11.76470588 1 3.7 3.5 1750 4 7800 1000 14.70588235 1
A4405 Saraswathi 19.44444444 1 1.8 1.3 260 4 6800 -3000 -30.6122449 1
A4407 Parameswari.K 22.80701754 1 1.6 1.15 255.5555556 4 5900 -3000 -33.70786517 1
A4447 Indra.R 2.380952381 1 2.1 1.5 250 4 4900 3700 308.3333333 4
A4450 Indhirani. P 17.24137931 1 1.2 1.1 1100 4 3600 2800 350 4
A4472 Krishnaveni.M 68.18181818 2 1.8 0.2 12.5 1 6700 -100 -1.470588235 1
A4477 Geetha.R 41.66666667 1 2.9 -1.1 -27.5 1 8700 -500 -5.434782609 1
A4539 Gomathy.K -2.325581395 1 1.1 1.06 2650 4 4700 -5200 -52.52525253 1
A4585 Raj. D -4.255319149 1 1.9 1.71 900 4 6900 -4100 -37.27272727 1
A4591 Vimalraj.P 3.125 1 2.3 1.42 161.3636364 4 7800 1000 14.70588235 1
A4638 Radha -5.263157895 1 3.4 2.95 655.5555556 4 6000 -3800 -38.7755102 1
A4648 Prithivi.M 9.756097561 1 2.6 2.12 441.6666667 4 8000 -2800 -25.92592593 1
A4651 Vijayalakshmi. R 65.38461538 2 3.6 0.7 24.13793103 1 9000 1500 20 1
A4671 Chithra.C -13.33333333 1 2.9 2.15 286.6666667 4 5800 -4000 -40.81632653 1
A4675 Balasubramaniam 7.692307692 1 3.6 1.2 50 2 7800 1000 14.70588235 1
A4704 Radhika.A     -2.325581395 1 2.6 1.68 182.6086957 4 2700 -4200 -60.86956522 1
A4726 Kousalya.N -11.36363636 1 2.3 1.7 283.3333333 4 1200 -300 -20 1
A4829 Sathishkumar.C 7.894736842 1 2 1.65 471.4285714 4 3400 -5400 -61.36363636 1
A4849 Chinnasamy. A 17.85714286 1 3.5 1.2 52.17391304 2 5400 -1000 -15.625 1
A4868 Kadeswari 25 1 1.9 0.2 11.76470588 1 5600 -2800 -33.33333333 1
A4872 Rajendran.P 26.66666667 1 2.5 0 0 1 6700 -3290 -32.93293293 1
A5148 BEENA.J 36.66666667 1 2.9 2.02 229.5454545 4 9000 2100 30.43478261 1
44.42389957 292.2711925 46.96995005
0 1 0 1 0 1
50 2 50 2 50 2
100 3 100 3 100 3
150 4 150 4 150 4
